Omnicell (OMCL) 10-Q5 Nov 212021 Q3 Quarterly reportFinancial data

Company Profile

Cover

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2021	Oct. 29, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	000-33043
Entity Registrant Name	OMNICELL, INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-3166458
Entity Address, Address Line One	590 East Middlefield Road
Entity Address, City or Town	Mountain View
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94043
City Area Code	650
Local Phone Number	251-6100
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	OMCL
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		43,942,668
Entity Central Index Key	0000926326
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 481,549	$ 485,928
Accounts receivable and unbilled receivables, net of allowances of $4,396 and $4,286, respectively	233,729	190,117
Inventories	104,259	96,298
Prepaid expenses	24,762	16,027
Other current assets	44,417	41,044
Total current assets	888,716	829,414
Property and equipment, net	64,955	59,073
Long-term investment in sales-type leases, net	19,187	22,156
Operating lease right-of-use assets	48,973	55,114
Goodwill	616,387	499,309
Intangible assets, net	218,956	168,211
Long-term deferred tax assets	15,866	15,019
Prepaid commissions	57,949	56,919
Other long-term assets	120,482	119,289
Total assets	2,051,471	1,824,504
Current liabilities:
Accounts payable	74,656	40,309
Accrued compensation	45,044	55,750
Accrued liabilities	104,236	80,311
Deferred revenues, net	114,726	100,053
Total current liabilities	338,662	276,423
Long-term deferred revenues	14,141	5,673
Long-term deferred tax liabilities	53,313	39,633
Long-term operating lease liabilities	40,436	48,897
Other long-term liabilities	10,761	19,174
Convertible senior notes, net	482,822	467,201
Total liabilities	940,135	857,001
Commitments and contingencies (Note 13)
Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued	0	0
Common stock, $0.001 par value, 100,000 shares authorized; 53,763 and 52,677 shares issued; 43,869 and 42,783 shares outstanding, respectively	54	53
Treasury stock at cost, 9,894 outstanding, respectively	(238,109)	(238,109)
Additional paid-in capital	1,002,591	920,359
Retained earnings	354,590	290,722
Accumulated other comprehensive loss	(7,790)	(5,522)
Total stockholders’ equity	1,111,336	967,503
Total liabilities and stockholders’ equity	$ 2,051,471	$ 1,824,504

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Allowance for credit losses on accounts receivable and unbilled receivables	$ 4,396	$ 4,286
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common Stock, shares issued (in shares)	53,763,000	52,677,000
Common stock, shares outstanding (in shares)	43,869,000	42,783,000
Treasury stock, shares outstanding (in shares)	9,894,000	9,894,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenues	$ 296,402	$ 213,699	$ 820,984	$ 643,006
Cost of revenues	149,623	116,908	415,624	353,368
Gross profit	146,779	96,791	405,360	289,638
Operating expenses:
Research and development	19,477	15,197	53,770	54,679
Selling, general, and administrative	97,910	71,442	273,672	219,647
Total operating expenses	117,387	86,639	327,442	274,326
Income from operations	29,392	10,152	77,918	15,312
Interest and other income (expense), net	(6,065)	809	(18,715)	161
Income before provision for income taxes	23,327	10,961	59,203	15,473
Provision for (benefit from) income taxes	(5,990)	2,156	(4,665)	(344)
Net income	$ 29,317	$ 8,805	$ 63,868	$ 15,817
Net income per share:
Basic (in dollars per share)	$ 0.67	$ 0.21	$ 1.48	$ 0.37
Diluted (in dollars per share)	$ 0.61	$ 0.20	$ 1.35	$ 0.36
Weighted-average shares outstanding:
Basic (in shares)	43,648	42,802	43,293	42,606
Diluted (in shares)	48,341	43,691	47,195	43,651
Product revenues
Revenues	$ 213,970	$ 151,337	$ 589,006	$ 460,352
Cost of revenues	110,743	86,689	303,597	262,740
Services and other revenues
Revenues	82,432	62,362	231,978	182,654
Cost of revenues	$ 38,880	$ 30,219	$ 112,027	$ 90,628

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Statement of Comprehensive Income [Abstract]
Net income	$ 29,317	$ 8,805	$ 63,868	$ 15,817
Other comprehensive income (loss):
Foreign currency translation adjustments	(2,299)	3,510	(2,268)	(733)
Other comprehensive income (loss)	(2,299)	3,510	(2,268)	(733)
Comprehensive income	$ 27,018	$ 12,315	$ 61,600	$ 15,084

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Cumulative effect of a change in accounting principle related to credit losses	Common Stock	Treasury Stock	Additional Paid-In Capital	Accumulated Earnings	Accumulated EarningsCumulative effect of a change in accounting principle related to credit losses	Accumulated Other Comprehensive Income (Loss)
Balance at beginning of period (in shares) at Dec. 31, 2019			51,277,000
Balance at beginning of period at Dec. 31, 2019	$ 845,254	$ (264)	$ 51	$ (185,074)	$ 780,931	$ 258,792	$ (264)	$ (9,446)
Balance at beginning of period, Treasury stock (in shares) at Dec. 31, 2019				(9,145,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	11,311					11,311
Other comprehensive income (loss)	(4,694)							(4,694)
Share-based compensation	10,659				10,659
Issuance of common stock under employee stock plans (in shares)			474,000
Issuance of common stock under employee stock plans	17,659		$ 1		17,658
Tax payments related to restricted stock units	(1,425)				(1,425)
Balance at end of period (in shares) at Mar. 31, 2020			51,751,000
Balance at end of period at Mar. 31, 2020	878,500		$ 52	$ (185,074)	807,823	269,839		(14,140)
Balance at end of period, Treasury stock (in shares) at Mar. 31, 2020				(9,145,000)
Balance at beginning of period (in shares) at Dec. 31, 2019			51,277,000
Balance at beginning of period at Dec. 31, 2019	845,254	$ (264)	$ 51	$ (185,074)	780,931	258,792	$ (264)	(9,446)
Balance at beginning of period, Treasury stock (in shares) at Dec. 31, 2019				(9,145,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	15,817
Other comprehensive income (loss)	(733)
Balance at end of period (in shares) at Sep. 30, 2020			52,168,000
Balance at end of period at Sep. 30, 2020	918,399		$ 52	$ (238,109)	892,290	274,345		(10,179)
Balance at end of period, Treasury stock (in shares) at Sep. 30, 2020				(9,894,000)
Balance at beginning of period (in shares) at Mar. 31, 2020			51,751,000
Balance at beginning of period at Mar. 31, 2020	878,500		$ 52	$ (185,074)	807,823	269,839		(14,140)
Balance at beginning of period, Treasury stock (in shares) at Mar. 31, 2020				(9,145,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(4,299)					(4,299)
Other comprehensive income (loss)	451							451
Share-based compensation	11,351				11,351
Issuance of common stock under employee stock plans (in shares)			151,000
Issuance of common stock under employee stock plans	3,503				3,503
Tax payments related to restricted stock units	(2,045)				(2,045)
Balance at end of period (in shares) at Jun. 30, 2020			51,902,000
Balance at end of period at Jun. 30, 2020	887,461		$ 52	$ (185,074)	820,632	265,540		(13,689)
Balance at end of period, Treasury stock (in shares) at Jun. 30, 2020				(9,145,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	8,805					8,805
Other comprehensive income (loss)	3,510							3,510
Share-based compensation	11,024				11,024
Issuance of common stock under employee stock plans (in shares)			266,000
Issuance of common stock under employee stock plans	12,064				12,064
Tax payments related to restricted stock units	(631)				(631)
Stock repurchases (in shares)				(749,000)
Stock repurchases	(53,035)			$ (53,035)
Equity component of convertible senior note issuance, net of issuance costs	97,830				97,830
Purchase of convertible note hedge	(100,625)				(100,625)
Sale of warrants related to convertible senior notes	51,290				51,290
Tax benefits related to convertible senior notes	706				706
Balance at end of period (in shares) at Sep. 30, 2020			52,168,000
Balance at end of period at Sep. 30, 2020	$ 918,399		$ 52	$ (238,109)	892,290	274,345		(10,179)
Balance at end of period, Treasury stock (in shares) at Sep. 30, 2020				(9,894,000)
Balance at beginning of period (in shares) at Dec. 31, 2020	42,783,000		52,677,000
Balance at beginning of period at Dec. 31, 2020	$ 967,503		$ 53	$ (238,109)	920,359	290,722		(5,522)
Balance at beginning of period, Treasury stock (in shares) at Dec. 31, 2020	(9,894,000)			(9,894,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	$ 14,127					14,127
Other comprehensive income (loss)	(621)							(621)
Share-based compensation	11,772				11,772
Issuance of common stock under employee stock plans (in shares)			388,000
Issuance of common stock under employee stock plans	20,826				20,826
Tax payments related to restricted stock units	(2,596)				(2,596)
Balance at end of period (in shares) at Mar. 31, 2021			53,065,000
Balance at end of period at Mar. 31, 2021	$ 1,011,011		$ 53	$ (238,109)	950,361	304,849		(6,143)
Balance at end of period, Treasury stock (in shares) at Mar. 31, 2021				(9,894,000)
Balance at beginning of period (in shares) at Dec. 31, 2020	42,783,000		52,677,000
Balance at beginning of period at Dec. 31, 2020	$ 967,503		$ 53	$ (238,109)	920,359	290,722		(5,522)
Balance at beginning of period, Treasury stock (in shares) at Dec. 31, 2020	(9,894,000)			(9,894,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	$ 63,868
Other comprehensive income (loss)	$ (2,268)
Balance at end of period (in shares) at Sep. 30, 2021	43,869,000		53,763,000
Balance at end of period at Sep. 30, 2021	$ 1,111,336		$ 54	$ (238,109)	1,002,591	354,590		(7,790)
Balance at end of period, Treasury stock (in shares) at Sep. 30, 2021	(9,894,000)			(9,894,000)
Balance at beginning of period (in shares) at Mar. 31, 2021			53,065,000
Balance at beginning of period at Mar. 31, 2021	$ 1,011,011		$ 53	$ (238,109)	950,361	304,849		(6,143)
Balance at beginning of period, Treasury stock (in shares) at Mar. 31, 2021				(9,894,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	20,424					20,424
Other comprehensive income (loss)	652							652
Share-based compensation	13,039				13,039
Issuance of common stock under employee stock plans (in shares)			265,000
Issuance of common stock under employee stock plans	11,517				11,517
Tax payments related to restricted stock units	(4,071)				(4,071)
Balance at end of period (in shares) at Jun. 30, 2021			53,330,000
Balance at end of period at Jun. 30, 2021	1,052,572		$ 53	$ (238,109)	970,846	325,273		(5,491)
Balance at end of period, Treasury stock (in shares) at Jun. 30, 2021				(9,894,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	29,317					29,317
Other comprehensive income (loss)	(2,299)							(2,299)
Share-based compensation	13,666				13,666
Issuance of common stock under employee stock plans (in shares)			433,000
Issuance of common stock under employee stock plans	21,574		$ 1		21,573
Tax payments related to restricted stock units	$ (3,494)				(3,494)
Balance at end of period (in shares) at Sep. 30, 2021	43,869,000		53,763,000
Balance at end of period at Sep. 30, 2021	$ 1,111,336		$ 54	$ (238,109)	$ 1,002,591	$ 354,590		$ (7,790)
Balance at end of period, Treasury stock (in shares) at Sep. 30, 2021	(9,894,000)			(9,894,000)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Operating Activities
Net income	$ 63,868	$ 15,817
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	53,140	43,903
Loss on disposal of property and equipment	297	0
Share-based compensation expense	38,477	33,034
Deferred income taxes	2,042	(3,643)
Amortization of operating lease right-of-use assets	8,764	7,692
Amortization of debt issuance costs	2,570	754
Amortization of discount on convertible senior notes	13,874	249
Changes in operating assets and liabilities:
Accounts receivable and unbilled receivables	(39,561)	29,653
Inventories	(10,138)	4,570
Prepaid expenses	(8,229)	(6,272)
Other current assets	(1,059)	(6,617)
Investment in sales-type leases	2,686	(3,273)
Prepaid commissions	(1,030)	2,213
Other long-term assets	2,567	(4,023)
Accounts payable	33,111	(8,659)
Accrued compensation	(12,018)	(8,377)
Accrued liabilities	20,149	3,281
Deferred revenues	21,225	8,827
Operating lease liabilities	(9,392)	(7,764)
Other long-term liabilities	(9,166)	8,057
Net cash provided by operating activities	172,177	109,422
Investing Activities
Software development for external use	(24,141)	(25,909)
Purchases of property and equipment	(17,892)	(17,265)
Business acquisition, net of cash acquired	(178,080)	0
Net cash used in investing activities	(220,113)	(43,174)
Financing Activities
Proceeds from revolving credit facility	0	150,000
Repayment of revolving credit facility	0	(200,000)
Payments for debt issuance costs for revolving credit facility	0	(550)
Proceeds from issuance of convertible senior notes, net of issuance costs	0	559,665
Purchase of convertible note hedge	0	(100,625)
Proceeds from sale of warrants	0	51,290
Proceeds from issuances under stock-based compensation plans	53,917	33,226
Employees’ taxes paid related to restricted stock units	(10,161)	(4,101)
Change in customer funds, net	(3,059)	0
Stock repurchases	0	(53,035)
Net cash provided by financing activities	40,697	435,870
Effect of exchange rate changes on cash and cash equivalents	(492)	(157)
Net increase (decrease) in cash, cash equivalents, and restricted cash	(7,731)	501,961
Cash, cash equivalents, and restricted cash at beginning of period	489,920	127,210
Cash, cash equivalents, and restricted cash at end of period	482,189	629,171
Reconciliation of cash, cash equivalents, and restricted cash to the Condensed Consolidated Balance Sheets:
Cash and cash equivalents	481,549	629,171
Restricted cash included in Other current assets	640	0
Cash, cash equivalents, and restricted cash at end of period	482,189	629,171
Supplemental disclosure of non-cash activities
Unpaid purchases of property and equipment	691	319
Transfers between inventory and property and equipment, net	$ 1,876	$ 0

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	9 Months Ended
Organization and Summary of Significant Accounting Policies	Sep. 30, 2021
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	Organization and Summary of Significant Accounting Policies Business Omnicell, Inc. was incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. The Company’s major products and related services are medication management automation solutions and adherence tools for healthcare systems and pharmacies, which are sold in its principal market, the healthcare industry. The Company’s market is primarily located in the United States and Europe. “Omnicell” or the “Company” collectively refer to Omnicell, Inc. and its subsidiaries. Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of the Company as of September 30, 2021 and December 31, 2020, the results of operations and comprehensive income for the three and nine months ended September 30, 2021 and 2020, and cash flows for the nine months ended September 30, 2021 and 2020. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) have been condensed or omitted in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying Notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on February 24, 2021, except as discussed in the section entitled “Recently Adopted Authoritative Guidance” below. The Company’s results of operations and comprehensive income for the three and nine months ended September 30, 2021, and cash flows for the nine months ended September 30, 2021 are not necessarily indicative of results that may be expected for the year ending December 31, 2021, or for any future period. Principles of Consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. On September 9, 2021, the Company completed its acquisition of RxInnovation Inc., operating as FDS Amplicare (“FDS Amplicare”). The Condensed Consolidated Financial Statements include the results of operations of this recently acquired company, commencing as of the acquisition date. The significant accounting policies of the acquired business have been aligned to conform to the accounting policies of Omnicell. Reclassifications and Adjustments Certain prior-year amounts have been reclassified to conform with current-period presentation. This reclassification was a change in the presentation of certain items in the disaggregation of revenues for the three and nine months ended September 30, 2020 in Note 3, Revenues . This change was not deemed material and was included to conform with current-period classification and presentation. Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s Condensed Consolidated Financial Statements and accompanying Notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. The Company’s critical accounting policies are those that affect its financial statements materially and involve difficult, subjective, or complex judgments by management. As of September 30, 2021, the Company is not aware of any events or circumstances that would require an update to its estimates, judgments, or revisions to the carrying value of its assets or liabilities. Segment Reporting The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company's Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company at the consolidated level using information about its revenues, gross profit, income from operations, and other key financial data. All significant operating decisions are based upon an analysis of the Company as one operating segment, which is the same as its reporting segment. Recently Adopted Authoritative Guidance In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes . The update simplifies the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (“ASC”) 740, Income Taxes , as well as improves consistent application of and simplifies the guidance for other areas of ASC 740 by clarifying and amending existing guidance. The Company adopted ASU 2019-12 on January 1, 2021 on a prospective basis. The adoption of this guidance did not have a material impact on the Company’s Condensed Consolidated Financial Statements. Recently Issued Authoritative Guidance In August 2020, the FASB issued ASU 2020-06 Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40) . The update simplifies the accounting for convertible debt instruments by reducing the number of accounting models and the number of embedded conversion features that could be recognized separately from the primary contract. ASU 2020-06 also enhances transparency and improves disclosures for convertible instruments and earnings per share guidance. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company will adopt ASU 2020-06 on January 1, 2022, and expects to use the modified retrospective method of transition. The Company’s adoption of the update is estimated to result in an increase in convertible senior notes, net of issuance costs, of $75.4 million; a decrease in additional paid-in capital of $72.7 million; a decrease of long-term deferred tax liabilities of $19.8 million; a decrease in long-term deferred tax assets of $0.5 million; and an increase in retained earnings of $16.7 million, all as of January 1, 2022. There was no other recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s Condensed Consolidated Financial Statements through the reporting date.

Business Combinations

Business Combinations	9 Months Ended
Business Combinations	Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Business Combinations	Business Combinations FDS Amplicare Acquisition On September 9, 2021, the Company completed its acquisition of all of the outstanding equity interests in FDS Amplicare, pursuant to the terms and conditions of the Agreement and Plan of Merger, dated July 25, 2021, by and among FDS Amplicare, Omnicell, Inc., Fleming Acquisition Corp., and the representative of the securityholders for a base purchase price of $177.0 million, prior to post-closing adjustments for closing cash, net working capital, and assumed indebtedness, which is expected to be finalized in the fourth quarter of 2021. The following table summarizes the preliminary purchase price for the FDS Amplicare acquisition: FDS Amplicare (In thousands) Base purchase price $ 177,000 Add: Estimated closing cash 859 Add: Estimated net working capital adjustment 1,333 Less: Assumed indebtedness (647) Total purchase price transferred $ 178,545 The FDS Amplicare acquisition adds a comprehensive and complementary suite of software-as-a-services (“SaaS”) financial management, analytics, and population health solutions to Omnicell’s EnlivenHealth TM offering. The results of FDS Amplicare’s operations have been included in the Company’s consolidated results of operations, commencing as of the acquisition date. The Company accounted for the acquisition of FDS Amplicare in accordance with ASC 805, Business Combinations . The tangible and intangible assets acquired and liabilities assumed were recorded at fair value on the acquisition date. The preliminary fair values assume management’s best estimates based on information available at the acquisition date and may change over the measurement period, which will end no later than one year from the acquisition date, as additional information is received. The following table represents the preliminary allocation of the purchase price to the assets acquired and the liabilities assumed by the Company as part of the acquisition included in the Company’s Condensed Consolidated Balance Sheets, and is reconciled to the purchase price transferred: FDS Amplicare (In thousands) Cash and cash equivalents $ 465 Accounts receivable and unbilled receivables 4,235 Prepaid expenses 506 Other current assets 45 Total current assets 5,251 Property and equipment 444 Operating lease right-of-use assets 2,252 Goodwill 118,846 Intangible assets 69,600 Other long-term assets 51 Total assets 196,444 Accounts payable 950 Accrued compensation 1,312 Accrued liabilities 1,396 Deferred revenues 1,916 Long-term deferred tax liabilities 11,275 Long-term operating lease liabilities 920 Other long-term liabilities 130 Total liabilities 17,899 Total purchase price $ 178,545 Total purchase price, net of cash acquired $ 178,080 The $118.8 million of goodwill arising from the FDS Amplicare acquisition is primarily attributed to sales of future SaaS solutions and FDS Amplicare’s assembled workforce. None of the goodwill is expected to be deductible for tax purposes. Intangible assets eligible for recognition separate from goodwill were those that satisfied either the contractual or legal criterion or the separability criterion in the accounting guidance. The identifiable intangible assets acquired and their estimated useful lives for amortization are as follows: FDS Amplicare Fair value Useful life (In thousands, except for years) Customer relationships $ 59,500 23 Acquired technology 7,700 5 - 7 Trade names 2,400 5 Total purchased intangible assets $ 69,600 The customer relationships intangible asset represents the fair value of the underlying relationships and agreements with FDS Amplicare’s customers. The acquired technology intangible assets represent the fair value of FDS Amplicare’s portfolio of SaaS solutions that have reached technological feasibility and were part of FDS Amplicare’s offerings at the acquisition date. The trade names intangible asset represents the fair value of brand and name recognition associated with the marketing of certain FDS Amplicare SaaS solutions. The fair value of the customer relationships intangible asset was determined based on the excess earnings method, and the fair values of the acquired technology and trade names intangible assets were determined based on the relief-from-royalty method. The key assumptions used in estimating the fair values of intangible assets included forecasted financial information; customer attrition rates; royalty rates of 10.0% and 2.0% for the acquired technology and trade names intangible assets, respectively; a discount rate of 13.0% for all intangible assets; and certain other assumptions. The customer relationships and acquired technology intangible assets are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained. The trade names intangible asset is being amortized over its estimated useful life using the straight-line method of amortization. The Company believes that the fair values assigned to the assets acquired and liabilities assumed are based on reasonable assumptions and estimates that market participants would use. Actual results may differ from these estimates and assumptions. The Company incurred approximately $4.6 million and $6.6 million in acquisition-related costs related to the FDS Amplicare acquisition during the three and nine months ended September 30, 2021, respectively. These costs were expensed as incurred, and are included in selling, general, and administrative expenses in the Company’s Condensed Consolidated Statements of Operations. 340B Link Business Acquisition On October 1, 2020, the Company completed the acquisition of all of the outstanding equity of the 340B Link business (the “340B Link Business”) of Pharmaceutical Strategies Group, LLC pursuant to the terms and conditions of the Equity Purchase Agreement, dated August 11, 2020, as amended, by and among Omnicell, Inc., PSGH, LLC, BW Apothecary Holdings, LLC, the sellers identified therein, and the sellers’ representative for total cash consideration of $225.0 million. The 340B Link Business acquisition adds a comprehensive and differentiated suite of software-enabled services and solutions used by certain eligible hospitals, health systems, clinics, and entities to manage compliance and capture 340B drug cost savings on outpatient prescriptions filled through the eligible entity’s pharmacy or a contracted pharmacy partner. The results of the 340B Link Business’s operations have been included in the Company’s consolidated results of operations, commencing as of the acquisition date. The Company accounted for the acquisition of the 340B Link Business in accordance with ASC 805. The tangible and intangible assets acquired and liabilities assumed were recorded at fair value on the acquisition date. The following table represents the allocation of the purchase price to the assets acquired and the liabilities assumed by the Company as part of the acquisition included in the Company’s Condensed Consolidated Balance Sheets, and is reconciled to the purchase price transferred: 340B Link Business (In thousands) Accounts receivable and unbilled receivables $ 8,197 Prepaid expenses 232 Other current assets (1) 23,040 Total current assets 31,469 Property and equipment 531 Operating lease right-of-use assets 3,138 Goodwill (1) 160,268 Intangible assets 62,800 Total assets 258,206 Accounts payable 568 Accrued liabilities (1) 23,715 Long-term deferred tax liabilities (1) 6,334 Long-term operating lease liabilities 2,589 Total liabilities 33,206 Total purchase price $ 225,000 _________________________________________________ (1) During the third quarter of 2021, the Company recorded measurement period adjustments of $0.9 million to goodwill, consisting of an increase in other current assets, a decrease in accrued liabilities, and a decrease in long-term deferred tax liabilities of $0.3 million, $0.1 million, and $0.5 million, respectively. The $160.3 million of goodwill arising from the 340B Link Business acquisition is primarily attributed to sales of future software-enabled services and solutions and the 340B Link Business’s assembled workforce. Goodwill that is expected to be deductible for tax purposes is approximately $93.7 million. Intangible assets eligible for recognition separate from goodwill were those that satisfied either the contractual or legal criterion or the separability criterion in the accounting guidance. The identifiable intangible assets acquired and their estimated useful lives for amortization are as follows: 340B Link Business Fair value Useful life (In thousands, except for years) Customer relationships $ 53,000 21 Acquired technology 9,000 5 Trade names 200 1 Non-compete agreements 600 3 Total purchased intangible assets $ 62,800 The customer relationships intangible asset represents the fair value of the underlying relationships and agreements with the 340B Link Business’s customers. The acquired technology intangible asset represents the fair value of the 340B Link Business’s portfolio of software and solutions that have reached technological feasibility and were part of the 340B Link Business’s offerings at the acquisition date. The trade names intangible asset represents the fair value of brand and name recognition associated with the marketing of the 340B Link Business’s software-enabled services and solutions. The non-compete agreements intangible asset represents the fair value of non-compete agreements with former key members of the 340B Link Business’s management. The fair value of the customer relationships intangible asset was determined based on the excess earnings method; the fair values of the acquired technology and trade names intangible assets were determined based on the relief-from-royalty method; and the fair value of the non-compete agreements intangible asset was determined based on the lost profits method. The key assumptions used in estimating the fair values of intangible assets included forecasted financial information; customer attrition rates; royalty rates of 10.0% and 0.5% for the acquired technology and trade names intangible assets, respectively; a discount rate of 14.0% for all intangible assets; and certain other assumptions. The customer relationships and acquired technology intangible assets are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained. The trade names and non-compete agreements are being amortized over their estimated useful lives using the straight-line method of amortization. The Company believes that the fair values assigned to the assets acquired and liabilities assumed are based on reasonable assumptions and estimates that market participants would use. Actual results may differ from these estimates and assumptions. The Company incurred approximately $3.9 million in acquisition-related costs related to the 340B Link Business acquisition during the nine months ended September 30, 2020. These costs were expensed as incurred, and are included in selling, general, and administrative expenses in the Company’s Condensed Consolidated Statements of Operations. Pro Forma Financial Information The following table presents certain unaudited pro forma consolidated financial information for the three and nine months ended September 30, 2021 and 2020 as if the FDS Amplicare acquisition had been completed on January 1, 2020 and the 340B Link Business acquisition had been completed on January 1, 2019. The unaudited pro forma financial information is presented for informational purposes only, and is not indicative of what would have occurred had the FDS Amplicare acquisition and the 340B Link Business acquisition taken place on January 1, 2020 and January 1, 2019, respectively. The unaudited pro forma financial information combines the historical results of the acquisitions with the Company’s consolidated historical results and includes certain adjustments including, but not limited to, amortization and depreciation of intangible assets and property and equipment acquired; imputed interest, interest expense, and amortization of debt issuance costs related to acquisitions, as applicable; and certain acquisition-related costs incurred. Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 (In thousands) Pro forma revenues $ 302,114 $ 230,099 $ 840,896 $ 689,208 Pro forma net income $ 32,050 $ 10,350 $ 65,194 $ 8,476

Revenues

Revenues	9 Months Ended
Revenues	Sep. 30, 2021
Revenue Recognition [Abstract]
Revenues	Revenues Revenue Recognition The Company earns revenues from sales of its products and related services, which are sold in the healthcare industry, its principal market. The Company’s customer arrangements typically include one or more of the following revenue categories: Connected devices, software licenses, and other. Software-enabled connected devices and software licenses that manage and regulate the storage and dispensing of pharmaceuticals, consumables blister cards, and packaging equipment and other supplies. This revenue category is often sold through long-term, sole-source agreements with multi-year co-development plans. Solutions in this category include, but are not limited to, XT Series automated dispensing systems, the XR2 Automated Central Pharmacy System, and IV compounding automation solutions. Technical services. Post-installation technical support and other related services, including phone support, on-site service, parts, and access to unspecified software updates and enhancements, if and when available. This revenue category is often supported by multi-year or annual contractual agreements. Consumables. Medication adherence packaging, labeling, and other one-time use packaging including multimed adherence packaging and single dose blister cards which are used by retail, community, and outpatient pharmacies, as well as by institutional pharmacies serving long-term care and other sites outside the acute care hospital, and are designed to improve patient engagement and adherence to prescriptions. SaaS, subscription software, and technology-enabled services. Emerging software and service solutions which are offered on a subscription basis with fees typically based either on transaction volume or a fee over a specified period of time. Solutions in this category include, but are not limited to, EnlivenHealth (formerly Population Health Solutions) inclusive of newly acquired FDS Amplicare, 340B solutions, and services associated with Omnicell One™ (formerly Performance Center), Central Pharmacy Dispensing Services, including the XR2 Automated Central Pharmacy System, and Central Pharmacy Compounding Services, including IV compounding automation solutions. The following table summarizes revenue recognition for each revenue category: Revenue Category Timing of Revenue Recognition Income Statement Classification Connected devices, software licenses, and other Point in time, as transfer of control occurs, generally upon installation and acceptance by the customer Product Technical services Over time, as services are provided, typically ratably over the service term Service Consumables Point in time, as transfer of control occurs, generally upon shipment to or receipt by customer Product SaaS, subscription software, and technology-enabled services Over time, as services are provided Service A portion of the Company’s sales are made to customers who are members of Group Purchasing Organizations (“GPOs”) and Federal agencies that purchase under a Federal Supply Schedule contract with the Department of Veterans Affairs (the “GSA Contract”). GPOs are often owned fully or in part by the Company’s customers, and the Company pays fees to the GPO on completed contracts. The Company also pays the Industrial Funding Fee (“IFF”) to the Department of Veterans Affairs under the GSA Contract. The Company considers these fees consideration paid to customers and records them as reductions to revenue. Fees to GPOs and the IFF were $4.4 million and $2.3 million for the three months ended September 30, 2021 and 2020, respectively, and $12.0 million and $6.9 million for the nine months ended September 30, 2021 and 2020, respectively. Disaggregation of Revenues The following table summarizes the Company’s revenues disaggregated by revenue type for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 (In thousands) Connected devices, software licenses, and other $ 195,820 $ 135,037 $ 534,582 $ 403,761 Technical services 53,529 51,380 156,321 151,077 Consumables 18,150 16,300 54,424 56,591 SaaS, subscription software, and technology-enabled services 28,903 10,982 75,657 31,577 Total revenues $ 296,402 $ 213,699 $ 820,984 $ 643,006 The following table summarizes the Company’s revenues disaggregated by geographic region, which is determined based on customer location, for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 (In thousands) United States $ 271,276 $ 193,639 $ 738,411 $ 579,425 Rest of world (1) 25,126 20,060 82,573 63,581 Total revenues $ 296,402 $ 213,699 $ 820,984 $ 643,006 _________________________________________________ (1) No individual country represented more than 10% of total revenues. Contract Assets and Contract Liabilities The following table reflects the Company’s contract assets and contract liabilities: September 30, December 31, (In thousands) Short-term unbilled receivables, net (1) $ 17,879 $ 13,895 Long-term unbilled receivables, net (2) 14,460 17,205 Total contract assets $ 32,339 $ 31,100 Short-term deferred revenues, net $ 114,726 $ 100,053 Long-term deferred revenues 14,141 5,673 Total contract liabilities $ 128,867 $ 105,726 _________________________________________________ (1) Included in accounts receivable and unbilled receivables in the Condensed Consolidated Balance Sheets. (2) Included in other long-term assets in the Condensed Consolidated Balance Sheets. The portion of the transaction price allocated to the Company’s unsatisfied performance obligations for which invoicing has occurred is recorded as deferred revenues. Short-term deferred revenues of $114.7 million and $100.1 million include deferred revenues from product sales and service contracts, net of deferred cost of sales of $24.1 million and $21.0 million, as of September 30, 2021 and December 31, 2020, respectively. The short-term deferred revenues from product sales relate to delivered and invoiced products, pending installation and acceptance, expected to occur within the next twelve months. During the three and nine months ended September 30, 2021, the Company recognized revenues of $18.9 million and $90.0 million, respectively, that were included in the corresponding gross short-term deferred revenues balance of $121.1 million as of December 31, 2020. Long-term deferred revenues include deferred revenues from product and service contracts of $14.1 million and $5.7 million as of September 30, 2021 and December 31, 2020, respectively. Remaining performance obligations are primarily recognized ratably over the remaining term of the contract, generally not more than ten years. Significant Customers There were no customers that accounted for more than 10% of the Company’s total revenues for the three and nine months ended September 30, 2021 and 2020. Also, there were no customers that accounted for more than 10% of the Company’s accounts receivable balance as of September 30, 2021 and December 31, 2020.

Net Income Per Share

Net Income Per Share	9 Months Ended
Net Income Per Share	Sep. 30, 2021
Earnings Per Share [Abstract]
Net Income Per Share	Net Income Per Share Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of shares outstanding during the period. In periods of net loss, all potential common shares are anti-dilutive, so diluted net loss per share equals the basic net loss per share. In periods of net income, diluted net income per share is computed by dividing net income for the period by the basic weighted-average number of shares plus any dilutive potential common stock outstanding during the period, using the treasury stock method. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards, and restricted stock units, as well as shares the Company could be obligated to issue from its convertible senior notes and warrants, as described in Note 10, Convertible Senior Notes . Any anti-dilutive weighted-average dilutive shares related to stock award plans, convertible senior notes, and warrants are excluded from the computation of the diluted net income per share. The basic and diluted net income per share calculations for the three and nine months ended September 30, 2021 and 2020 were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 (In thousands, except per share data) Net income $ 29,317 $ 8,805 $ 63,868 $ 15,817 Weighted-average shares outstanding – basic 43,648 42,802 43,293 42,606 Effect of dilutive securities from stock award plans 2,087 889 2,086 1,045 Effect of convertible senior notes 2,156 — 1,816 — Effect of warrants 450 — — — Weighted-average shares outstanding – diluted 48,341 43,691 47,195 43,651 Net income per share – basic $ 0.67 $ 0.21 $ 1.48 $ 0.37 Net income per share – diluted $ 0.61 $ 0.20 $ 1.35 $ 0.36 Anti-dilutive weighted-average shares related to stock award plans 64 2,328 199 2,076 Anti-dilutive weighted-average shares related to convertible senior notes and warrants — 11,816 5,908 11,816

Cash and Cash Equivalents and F

Cash and Cash Equivalents and Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Cash and Cash Equivalents and Fair Value of Financial Instruments	Cash and Cash Equivalents and Fair Value of Financial Instruments Cash and cash equivalents of $481.5 million and $485.9 million as of September 30, 2021 and December 31, 2020, respectively, consisted of bank accounts and highly-liquid U.S. Government money market funds held in sweep and asset management accounts with major financial institutions. As of September 30, 2021 and December 31, 2020, cash equivalents were $449.1 million and $447.2 million, respectively, which consisted of money market funds held in sweep and asset management accounts. Fair Value Hierarchy The Company measures its financial instruments at fair value. The Company’s cash, cash equivalents, and restricted cash are classified within Level 1 of the fair value hierarchy as they are valued primarily using quoted market prices utilizing market observable inputs. The Company's credit facility is classified within Level 2 as the valuation inputs are based on quoted prices or market observable data of similar instruments. The Company's convertible senior notes are classified within Level 2 as the valuation inputs are based on quoted prices in an inactive market on the last day in the reporting period. As of September 30, 2021, the fair value of the convertible senior notes was $917.0 million, compared to their carrying value of $482.8 million, which is net of unamortized discount and debt issuance costs and excludes amounts classified within additional paid-in capital. Refer to Note 9, Debt and Credit Agreement, for further information regarding the Company’s credit facility and Note 10, Convertible Senior Notes, for further information regarding the Company’s convertible senior notes.

Balance Sheet Components

Balance Sheet Components	9 Months Ended
Balance Sheet Components	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Components	Balance Sheet Components Balance sheet details as of September 30, 2021 and December 31, 2020 are presented in the tables below: September 30, December 31, (In thousands) Inventories: Raw materials $ 40,844 $ 28,205 Work in process 7,591 7,973 Finished goods 55,824 60,120 Total inventories $ 104,259 $ 96,298 Other current assets: Funds held for customers, including restricted cash (1) $ 20,150 $ 18,164 Net investment in sales-type leases, current portion 10,529 10,246 Prepaid income taxes 5,706 10,095 Other current assets 8,032 2,539 Total other current assets $ 44,417 $ 41,044 Other long-term assets: Capitalized software, net $ 98,559 $ 94,027 Unbilled receivables, net 14,460 17,205 Deferred debt issuance costs 3,430 4,253 Other long-term assets 4,033 3,804 Total other long-term assets $ 120,482 $ 119,289 Accrued liabilities: Operating lease liabilities, current portion $ 13,009 $ 12,197 Customer fund liabilities 20,150 18,164 Advance payments from customers 8,201 6,981 Rebates and lease buyouts 39,743 21,815 Group purchasing organization fees 5,940 4,412 Taxes payable 2,049 3,520 Other accrued liabilities 15,144 13,222 Total accrued liabilities $ 104,236 $ 80,311 _________________________________________________ (1) Includes restricted cash of $0.6 million and $4.0 million as of September 30, 2021 and December 31, 2020, respectively. The following table summarizes the changes in accumulated balances of other comprehensive income (loss), which consisted of foreign currency translation adjustments, for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 (In thousands) Beginning balance $ (5,491) $ (13,689) $ (5,522) $ (9,446) Other comprehensive income (loss) (2,299) 3,510 (2,268) (733) Ending balance $ (7,790) $ (10,179) $ (7,790) $ (10,179)

Property and Equipment

Property and Equipment	9 Months Ended
Property and Equipment	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment The following table represents the property and equipment balances as of September 30, 2021 and December 31, 2020: September 30, December 31, (In thousands) Equipment $ 87,061 $ 81,034 Furniture and fixtures 6,999 7,498 Leasehold improvements 20,365 19,517 Software 57,575 50,230 Construction in progress 8,943 7,095 Property and equipment, gross 180,943 165,374 Accumulated depreciation and amortization (115,988) (106,301) Total property and equipment, net $ 64,955 $ 59,073 Depreciation and amortization expense of property and equipment was $5.2 million and $4.6 million for the three months ended September 30, 2021 and 2020, respectively, and $14.9 million and $13.6 million for the nine months ended September 30, 2021 and 2020, respectively. The geographic location of the Company's property and equipment, net, is based on the physical location in which it is located. The following table summarizes the geographic information for property and equipment, net, as of September 30, 2021 and December 31, 2020: September 30, December 31, (In thousands) United States $ 60,384 $ 53,203 Rest of world (1) 4,571 5,870 Total property and equipment, net $ 64,955 $ 59,073 _________________________________________________ (1) No individual country represented more than 10% of total property and equipment, net.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
Goodwill and Intangible Assets	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill The following table represents changes in the carrying amount of goodwill: December 31, Additions (1) 340B Link Business Measurement Period Adjustments (1) Foreign currency exchange rate fluctuations September 30, (In thousands) Goodwill $ 499,309 118,846 (849) (919) $ 616,387 _________________________________________________ (1) Refer to Note 2, Business Combinations , for further information. Intangible Assets, Net The carrying amounts and useful lives of intangible assets as of September 30, 2021 and December 31, 2020 were as follows: September 30, 2021 Gross carrying amount (1) Accumulated Foreign currency exchange rate fluctuations Net carrying Useful life (In thousands, except for years) Customer relationships $ 247,389 $ (73,845) $ (916) $ 172,628 10 - 30 Acquired technology 93,366 (52,631) 6 40,741 5 - 20 Trade names 9,400 (5,539) 14 3,875 1 - 12 Patents 2,890 (1,578) — 1,312 2 - 20 Non-compete agreements 600 (200) — 400 3 Total intangibles assets, net $ 353,645 $ (133,793) $ (896) $ 218,956 December 31, 2020 Gross carrying amount (1) Accumulated Foreign currency exchange rate fluctuations Net carrying Useful life (In thousands, except for years) Customer relationships $ 187,889 $ (64,254) $ (777) $ 122,858 10 - 30 Acquired technology 86,029 (44,851) 6 41,184 5 - 20 Backlog 1,150 (1,078) — 72 4 Trade names 7,850 (5,794) 14 2,070 1 - 12 Patents 2,930 (1,455) 2 1,477 2 - 20 Non-compete agreements 600 (50) — 550 3 Total intangibles assets, net $ 286,448 $ (117,482) $ (755) $ 168,211 _________________________________________________ (1) The differences in gross carrying amounts between periods are primarily due to additions of intangible assets in connection with the FDS Amplicare acquisition, partially offset by the write-off of certain fully amortized intangible assets. Amortization expense of intangible assets was $6.3 million and $4.4 million for the three months ended September 30, 2021 and 2020, respectively, and $18.7 million and $13.3 million for the nine months ended September 30, 2021 and 2020, respectively. The estimated future amortization expenses for amortizable intangible assets were as follows: September 30, (In thousands) Remaining three months of 2021 $ 7,818 2022 28,772 2023 25,580 2024 18,462 2025 16,670 Thereafter 121,654 Total $ 218,956

Debt and Credit Agreement

Debt and Credit Agreement	9 Months Ended
Debt and Credit Agreement	Sep. 30, 2021
Debt Disclosure [Abstract]
Debt and Credit Agreement	Debt and Credit Agreement 2019 Revolving Credit Facility On November 15, 2019, the Company entered into an Amended and Restated Credit Agreement (as subsequently amended as discussed below, the “A&R Credit Agreement”) with the lenders from time to time party thereto, Wells Fargo Securities, LLC, Citizens Bank, N.A., and JPMorgan Chase Bank, N.A., as joint lead arrangers, and Wells Fargo Bank, National Association, as administrative agent. The A&R Credit Agreement superseded the Company’s 2016 secured credit facility (the “Prior Credit Agreement”) and provides for (a) a five-year revolving credit facility of $500.0 million (the “Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to $250.0 million (the “Incremental Facility”). In addition, the A&R Credit Agreement includes a letter of credit sub-limit of up to $15.0 million and a swing line loan sub-limit of up to $25.0 million. The A&R Credit Agreement has an expiration date of November 15, 2024, upon which date all remaining outstanding borrowings will be due and payable. Loans under the Revolving Credit Facility bear interest, at the Company’s option, at a rate equal to either (a) the LIBOR Rate, plus an applicable margin ranging from 1.25% to 2.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the A&R Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50%, and (iii) LIBOR for an interest period of one month plus 1.00%, plus an applicable margin ranging from 0.25% to 1.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio. Undrawn commitments under the Revolving Credit Facility are subject to a commitment fee ranging from 0.15% to 0.30% per annum based on the Company’s Consolidated Total Net Leverage Ratio on the average daily unused portion of the Revolving Credit Facility. The applicable margin for, and certain other terms of, any term loans under the Incremental Facility will be determined prior to the incurrence of such loans. The Company is permitted to make voluntary prepayments at any time without payment of a premium or penalty. On September 22, 2020, the parties entered into an amendment (the “Amendment”) to the A&R Credit Agreement to, among other changes, permit the issuance of the convertible senior notes and the purchase of the convertible note hedge transactions, as described in Note 10, Convertible Senior Notes , expand the Company’s flexibility to repurchase its common stock and make other restricted payments, and replace the total net leverage covenant with a new secured net leverage covenant that requires the Company to maintain a consolidated secured net leverage ratio not to exceed 3.50:1 for the calendar quarters ending September 30, 2020, December 31, 2020, and March 31, 2021 and 3.00:1 for the calendar quarters ending thereafter. The A&R Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends, and other distributions. The A&R Credit Agreement contains financial covenants that require the Company and its subsidiaries to not exceed a maximum total secured net leverage ratio (as described above) and maintain a minimum interest coverage ratio. In addition, the A&R Credit Agreement contains certain customary events of default including, but not limited to, failure to pay interest, principal and fees, or other amounts when due, material misrepresentations or misstatements in any representation or warranty, covenant defaults, certain cross defaults to other material indebtedness, certain judgment defaults, and events of bankruptcy. The Company’s obligations under the A&R Credit Agreement and any swap obligations and banking services obligations owing to a lender (or an affiliate of a lender) are guaranteed by certain of its domestic subsidiaries and secured by substantially all of its and such subsidiary guarantors’ assets. In connection with entering into the A&R Credit Agreement, and as a condition precedent to borrowing loans thereunder, the Company and certain of the Company’s other direct and indirect subsidiaries have entered into certain ancillary agreements, including, but not limited to, a reaffirmation agreement, which amends certain terms of the existing collateral agreement and reaffirms their obligations under the existing guaranty agreement. The Company was in full compliance with all covenants as of September 30, 2021. The refinancing of the Prior Credit Agreement by means of the A&R Credit Agreement was evaluated in accordance with ASC 470-50, Debt - Modifications and Extinguishments . In determining whether the refinancing was to be accounted for as a debt extinguishment or a debt modification, the Company considered whether lenders within the syndicate remained the same or changed and whether the changes in debt terms were substantial. This assessment was performed on an individual lender basis within the syndicate. As a result, the refinancing was accounted for as a modification with the exception of certain lenders that exited the syndicate. The exit of certain lenders resulted in an immaterial write-off of existing unamortized debt issuance costs. The remaining unamortized debt issuance costs related to debt modification, along with the new deferred costs, will be amortized over the remaining term of the A&R Credit Agreement. In connection with the A&R Credit Agreement, the Company incurred and capitalized an additional $2.3 million of debt issuance costs. In connection with the Amendment on September 22, 2020, the Company incurred and capitalized an additional $0.6 million of debt issuance costs. The debt issuance costs are being amortized to interest expense using the straight-line method through 2024. Amortization expense related to debt issuance costs for credit agreements was approximately $0.3 million and $0.2 million for the three months ended September 30, 2021 and 2020, respectively, and approximately $0.8 million and $0.7 million for the nine months ended September 30, 2021 and 2020, respectively. The following table represents changes in the balance of the Company's deferred debt issuance costs: (In thousands) Balance as of December 31, 2020 $ 4,253 Additions — Amortization (823) Balance as of September 30, 2021 $ 3,430 As of each of September 30, 2021 and December 31, 2020, there was no outstanding balance for the Revolving Credit Facility. 0.25% Convertible Senior Notes due 2025 On September 25, 2020, the Company completed a private offering of $575.0 million aggregate principal amount of 0.25% convertible senior notes (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $75.0 million principal amount of the Notes. The Company received proceeds from the issuance of the Notes of $559.7 million, net of $15.3 million of transaction fees and other debt issuance costs. The Notes bear interest at a rate of 0.25% per year, payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2021. The Notes were issued pursuant to an indenture, dated September 25, 2020 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee. The Notes are general senior, unsecured obligations of the Company and will mature on September 15, 2025, unless earlier redeemed, repurchased, or converted. The Notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding May 15, 2025, only under the following circumstances: (i) during any fiscal quarter commencing after the fiscal quarter ended on December 31, 2020 (and only during such fiscal quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price for the Notes on each applicable trading day; (ii) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per $1,000 principal amount of the Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate for the Notes on each such trading day; (iii) if the Company calls such Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the Notes called (or deemed called) for redemption; and (iv) upon the occurrence of specified corporate events, as specified in the Indenture. On or after May 15, 2025 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders of the Notes may convert all or any portion of their Notes at any time, regardless of the foregoing conditions. During the three months ended September 30, 2021, the conditional conversion feature of the Notes was triggered, based on the price of the Company’s common stock, as the last reported sale price of the Company’s common stock was greater than or equal to 130% of the then applicable conversion price for the Notes for at least 20 trading days during the period of 30 consecutive trading days ending on September 30, 2021, the last trading day of the fiscal quarter. Accordingly, the Notes are convertible, in whole or in part, at the option of the holders during the fourth quarter of 2021. Whether the Notes will be convertible following the fourth fiscal quarter of 2021 will depend on the continued satisfaction of this condition or another conversion condition in the future. The Company continues to classify the Notes as a long-term liability in its Condensed Consolidated Financial Statements as of September 30, 2021 based on contractual settlement provisions. Upon conversion, the Company may satisfy its conversion obligation by paying or delivering, as the case may be, cash, shares of its common stock, or a combination of cash and shares of its common stock, at the Company’s election, in the manner and subject to the terms and conditions provided in the Indenture. The initial conversion rate for the Notes is 10.2751 shares of the Company’s common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $97.32 per share of the Company’s common stock, subject to adjustment under certain circumstances in accordance with the terms of the Indenture. In addition, following certain corporate events that occur prior to the maturity date of the Notes or if the Company delivers a notice of redemption in respect of the Notes, the Company will, under certain circumstances, increase the conversion rate of the Notes for a holder who elects to convert its Notes (or any portion thereof) in connection with such a corporate event or convert its Notes called (or deemed called) for redemption during the related redemption period (as defined in the Indenture), as the case may be. If the Company undergoes a fundamental change, holders may require, subject to certain exceptions, the Company to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. As of September 30, 2021, none of the criteria for a fundamental change or a conversion rate adjustment had been met. The Company may not redeem the Notes prior to September 20, 2023. The Company may redeem for cash all or any portion of the Notes, at its option, on or after September 20, 2023, if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price for the Notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company redeems less than all of the outstanding Notes, at least $150.0 million aggregate principal amount of Notes must be outstanding and not subject to redemption as of the date of the relevant notice of redemption. No sinking fund is provided for in the Notes. Convertible debt instruments that may be settled in cash are required to be separated into liability and equity components. The allocation to the liability component is based on the fair value of a similar instrument that does not contain an equity conversion option. Based on this debt-to-equity ratio, debt issuance costs are then allocated to the liability and equity components in a similar manner. Accordingly, at issuance, the Company allocated $461.8 million to the debt liability and $72.7 million to additional paid-in capital, net of applicable issuance costs and deferred taxes. The difference between the principal amount of the Notes and the liability component, inclusive of issuance costs, represents the debt discount, which the Company will amortize to interest expense over the term of the Notes using an effective interest rate of 4.18%. The determination of the discount rate required certain estimates and assumptions. As of September 30, 2021, the remaining life of the Notes and the related debt discount and issuance cost accretion is approximately 4.0 years. The maximum number of shares issuable upon conversion, including the effect of a fundamental change and subject to other conversion rate adjustments, would be 8.1 million shares. As of September 30, 2021, the if-converted value of the Notes exceeded the principal amount by $302.0 million. The Notes consisted of the following balances reported in the Condensed Consolidated Balance Sheets as of September 30, 2021 and December 31, 2020: September 30, December 31, (In thousands) Liability: Principal amount $ 575,000 $ 575,000 Unamortized discount (81,870) (95,744) Unamortized debt issuance costs (10,308) (12,055) Convertible senior notes, liability component $ 482,822 $ 467,201 Convertible senior notes, equity component (1) $ 72,732 $ 72,732 _________________________________________________ (1) Included in additional paid-in capital in the Condensed Consolidated Balance Sheets. The following table summarizes the components of interest expense resulting from the Notes recognized in interest and other income (expense), net in the Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2021: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 (In thousands) Contractual coupon interest $ 359 $ 20 $ 1,078 $ 20 Amortization of discount $ 4,679 $ 249 $ 13,874 $ 249 Amortization of debt issuance costs $ 589 $ 31 $ 1,747 $ 31 Convertible Note Hedge and Warrant Transactions In connection with the issuance of the Notes, the Company entered into convertible note hedge and warrant transactions with an affiliate of one of the initial purchasers of the Notes and certain other financial institutions (the “option counterparties”) with respect to the Company’s common stock. The convertible note hedge consists of an option for the Company to purchase up to approximately 5.9 million shares of the Company’s common stock, which is equal to the number of shares of the Company’s common stock underlying the Notes, at an initial strike price of approximately $97.32 per share. The convertible note hedge will expire upon the maturity of the Notes, if not earlier exercised or terminated. The cost of the convertible note hedge was approximately $100.6 million and was accounted for as an equity instrument, which was recorded in additional paid-in capital in the Condensed Consolidated Balance Sheets. The Company recorded a deferred tax asset of $25.8 million at issuance related to the convertible note hedge transaction. The convertible note hedge is expected generally to reduce the potential dilution to the Company’s common stock upon any conversion of Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted Notes. Separately from the convertible note hedge, the Company entered into warrant transactions to sell to the option counterparties warrants to acquire, subject to customary anti-dilution adjustments, up to approximately 5.9 million shares of its common stock in the aggregate at an initial strike price of $141.56 per share. The warrants require net share or net cash settlement upon the Company’s election. The Company received aggregate proceeds of approximately $51.3 million for the issuance of the warrants, which was recorded in additional paid-in capital at issuance in the Condensed Consolidated Balance Sheets. The warrants could separately have a dilutive effect to the Company’s common stock to the extent that the market price per share of its common stock exceeds the strike price of the warrants.

Convertible Senior Notes

Convertible Senior Notes	9 Months Ended
Convertible Senior Notes	Sep. 30, 2021
Debt Disclosure [Abstract]
Convertible Senior Notes	Debt and Credit Agreement 2019 Revolving Credit Facility On November 15, 2019, the Company entered into an Amended and Restated Credit Agreement (as subsequently amended as discussed below, the “A&R Credit Agreement”) with the lenders from time to time party thereto, Wells Fargo Securities, LLC, Citizens Bank, N.A., and JPMorgan Chase Bank, N.A., as joint lead arrangers, and Wells Fargo Bank, National Association, as administrative agent. The A&R Credit Agreement superseded the Company’s 2016 secured credit facility (the “Prior Credit Agreement”) and provides for (a) a five-year revolving credit facility of $500.0 million (the “Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to $250.0 million (the “Incremental Facility”). In addition, the A&R Credit Agreement includes a letter of credit sub-limit of up to $15.0 million and a swing line loan sub-limit of up to $25.0 million. The A&R Credit Agreement has an expiration date of November 15, 2024, upon which date all remaining outstanding borrowings will be due and payable. Loans under the Revolving Credit Facility bear interest, at the Company’s option, at a rate equal to either (a) the LIBOR Rate, plus an applicable margin ranging from 1.25% to 2.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the A&R Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50%, and (iii) LIBOR for an interest period of one month plus 1.00%, plus an applicable margin ranging from 0.25% to 1.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio. Undrawn commitments under the Revolving Credit Facility are subject to a commitment fee ranging from 0.15% to 0.30% per annum based on the Company’s Consolidated Total Net Leverage Ratio on the average daily unused portion of the Revolving Credit Facility. The applicable margin for, and certain other terms of, any term loans under the Incremental Facility will be determined prior to the incurrence of such loans. The Company is permitted to make voluntary prepayments at any time without payment of a premium or penalty. On September 22, 2020, the parties entered into an amendment (the “Amendment”) to the A&R Credit Agreement to, among other changes, permit the issuance of the convertible senior notes and the purchase of the convertible note hedge transactions, as described in Note 10, Convertible Senior Notes , expand the Company’s flexibility to repurchase its common stock and make other restricted payments, and replace the total net leverage covenant with a new secured net leverage covenant that requires the Company to maintain a consolidated secured net leverage ratio not to exceed 3.50:1 for the calendar quarters ending September 30, 2020, December 31, 2020, and March 31, 2021 and 3.00:1 for the calendar quarters ending thereafter. The A&R Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends, and other distributions. The A&R Credit Agreement contains financial covenants that require the Company and its subsidiaries to not exceed a maximum total secured net leverage ratio (as described above) and maintain a minimum interest coverage ratio. In addition, the A&R Credit Agreement contains certain customary events of default including, but not limited to, failure to pay interest, principal and fees, or other amounts when due, material misrepresentations or misstatements in any representation or warranty, covenant defaults, certain cross defaults to other material indebtedness, certain judgment defaults, and events of bankruptcy. The Company’s obligations under the A&R Credit Agreement and any swap obligations and banking services obligations owing to a lender (or an affiliate of a lender) are guaranteed by certain of its domestic subsidiaries and secured by substantially all of its and such subsidiary guarantors’ assets. In connection with entering into the A&R Credit Agreement, and as a condition precedent to borrowing loans thereunder, the Company and certain of the Company’s other direct and indirect subsidiaries have entered into certain ancillary agreements, including, but not limited to, a reaffirmation agreement, which amends certain terms of the existing collateral agreement and reaffirms their obligations under the existing guaranty agreement. The Company was in full compliance with all covenants as of September 30, 2021. The refinancing of the Prior Credit Agreement by means of the A&R Credit Agreement was evaluated in accordance with ASC 470-50, Debt - Modifications and Extinguishments . In determining whether the refinancing was to be accounted for as a debt extinguishment or a debt modification, the Company considered whether lenders within the syndicate remained the same or changed and whether the changes in debt terms were substantial. This assessment was performed on an individual lender basis within the syndicate. As a result, the refinancing was accounted for as a modification with the exception of certain lenders that exited the syndicate. The exit of certain lenders resulted in an immaterial write-off of existing unamortized debt issuance costs. The remaining unamortized debt issuance costs related to debt modification, along with the new deferred costs, will be amortized over the remaining term of the A&R Credit Agreement. In connection with the A&R Credit Agreement, the Company incurred and capitalized an additional $2.3 million of debt issuance costs. In connection with the Amendment on September 22, 2020, the Company incurred and capitalized an additional $0.6 million of debt issuance costs. The debt issuance costs are being amortized to interest expense using the straight-line method through 2024. Amortization expense related to debt issuance costs for credit agreements was approximately $0.3 million and $0.2 million for the three months ended September 30, 2021 and 2020, respectively, and approximately $0.8 million and $0.7 million for the nine months ended September 30, 2021 and 2020, respectively. The following table represents changes in the balance of the Company's deferred debt issuance costs: (In thousands) Balance as of December 31, 2020 $ 4,253 Additions — Amortization (823) Balance as of September 30, 2021 $ 3,430 As of each of September 30, 2021 and December 31, 2020, there was no outstanding balance for the Revolving Credit Facility. 0.25% Convertible Senior Notes due 2025 On September 25, 2020, the Company completed a private offering of $575.0 million aggregate principal amount of 0.25% convertible senior notes (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $75.0 million principal amount of the Notes. The Company received proceeds from the issuance of the Notes of $559.7 million, net of $15.3 million of transaction fees and other debt issuance costs. The Notes bear interest at a rate of 0.25% per year, payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2021. The Notes were issued pursuant to an indenture, dated September 25, 2020 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee. The Notes are general senior, unsecured obligations of the Company and will mature on September 15, 2025, unless earlier redeemed, repurchased, or converted. The Notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding May 15, 2025, only under the following circumstances: (i) during any fiscal quarter commencing after the fiscal quarter ended on December 31, 2020 (and only during such fiscal quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price for the Notes on each applicable trading day; (ii) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per $1,000 principal amount of the Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate for the Notes on each such trading day; (iii) if the Company calls such Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the Notes called (or deemed called) for redemption; and (iv) upon the occurrence of specified corporate events, as specified in the Indenture. On or after May 15, 2025 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders of the Notes may convert all or any portion of their Notes at any time, regardless of the foregoing conditions. During the three months ended September 30, 2021, the conditional conversion feature of the Notes was triggered, based on the price of the Company’s common stock, as the last reported sale price of the Company’s common stock was greater than or equal to 130% of the then applicable conversion price for the Notes for at least 20 trading days during the period of 30 consecutive trading days ending on September 30, 2021, the last trading day of the fiscal quarter. Accordingly, the Notes are convertible, in whole or in part, at the option of the holders during the fourth quarter of 2021. Whether the Notes will be convertible following the fourth fiscal quarter of 2021 will depend on the continued satisfaction of this condition or another conversion condition in the future. The Company continues to classify the Notes as a long-term liability in its Condensed Consolidated Financial Statements as of September 30, 2021 based on contractual settlement provisions. Upon conversion, the Company may satisfy its conversion obligation by paying or delivering, as the case may be, cash, shares of its common stock, or a combination of cash and shares of its common stock, at the Company’s election, in the manner and subject to the terms and conditions provided in the Indenture. The initial conversion rate for the Notes is 10.2751 shares of the Company’s common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $97.32 per share of the Company’s common stock, subject to adjustment under certain circumstances in accordance with the terms of the Indenture. In addition, following certain corporate events that occur prior to the maturity date of the Notes or if the Company delivers a notice of redemption in respect of the Notes, the Company will, under certain circumstances, increase the conversion rate of the Notes for a holder who elects to convert its Notes (or any portion thereof) in connection with such a corporate event or convert its Notes called (or deemed called) for redemption during the related redemption period (as defined in the Indenture), as the case may be. If the Company undergoes a fundamental change, holders may require, subject to certain exceptions, the Company to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. As of September 30, 2021, none of the criteria for a fundamental change or a conversion rate adjustment had been met. The Company may not redeem the Notes prior to September 20, 2023. The Company may redeem for cash all or any portion of the Notes, at its option, on or after September 20, 2023, if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price for the Notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company redeems less than all of the outstanding Notes, at least $150.0 million aggregate principal amount of Notes must be outstanding and not subject to redemption as of the date of the relevant notice of redemption. No sinking fund is provided for in the Notes. Convertible debt instruments that may be settled in cash are required to be separated into liability and equity components. The allocation to the liability component is based on the fair value of a similar instrument that does not contain an equity conversion option. Based on this debt-to-equity ratio, debt issuance costs are then allocated to the liability and equity components in a similar manner. Accordingly, at issuance, the Company allocated $461.8 million to the debt liability and $72.7 million to additional paid-in capital, net of applicable issuance costs and deferred taxes. The difference between the principal amount of the Notes and the liability component, inclusive of issuance costs, represents the debt discount, which the Company will amortize to interest expense over the term of the Notes using an effective interest rate of 4.18%. The determination of the discount rate required certain estimates and assumptions. As of September 30, 2021, the remaining life of the Notes and the related debt discount and issuance cost accretion is approximately 4.0 years. The maximum number of shares issuable upon conversion, including the effect of a fundamental change and subject to other conversion rate adjustments, would be 8.1 million shares. As of September 30, 2021, the if-converted value of the Notes exceeded the principal amount by $302.0 million. The Notes consisted of the following balances reported in the Condensed Consolidated Balance Sheets as of September 30, 2021 and December 31, 2020: September 30, December 31, (In thousands) Liability: Principal amount $ 575,000 $ 575,000 Unamortized discount (81,870) (95,744) Unamortized debt issuance costs (10,308) (12,055) Convertible senior notes, liability component $ 482,822 $ 467,201 Convertible senior notes, equity component (1) $ 72,732 $ 72,732 _________________________________________________ (1) Included in additional paid-in capital in the Condensed Consolidated Balance Sheets. The following table summarizes the components of interest expense resulting from the Notes recognized in interest and other income (expense), net in the Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2021: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 (In thousands) Contractual coupon interest $ 359 $ 20 $ 1,078 $ 20 Amortization of discount $ 4,679 $ 249 $ 13,874 $ 249 Amortization of debt issuance costs $ 589 $ 31 $ 1,747 $ 31 Convertible Note Hedge and Warrant Transactions In connection with the issuance of the Notes, the Company entered into convertible note hedge and warrant transactions with an affiliate of one of the initial purchasers of the Notes and certain other financial institutions (the “option counterparties”) with respect to the Company’s common stock. The convertible note hedge consists of an option for the Company to purchase up to approximately 5.9 million shares of the Company’s common stock, which is equal to the number of shares of the Company’s common stock underlying the Notes, at an initial strike price of approximately $97.32 per share. The convertible note hedge will expire upon the maturity of the Notes, if not earlier exercised or terminated. The cost of the convertible note hedge was approximately $100.6 million and was accounted for as an equity instrument, which was recorded in additional paid-in capital in the Condensed Consolidated Balance Sheets. The Company recorded a deferred tax asset of $25.8 million at issuance related to the convertible note hedge transaction. The convertible note hedge is expected generally to reduce the potential dilution to the Company’s common stock upon any conversion of Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted Notes. Separately from the convertible note hedge, the Company entered into warrant transactions to sell to the option counterparties warrants to acquire, subject to customary anti-dilution adjustments, up to approximately 5.9 million shares of its common stock in the aggregate at an initial strike price of $141.56 per share. The warrants require net share or net cash settlement upon the Company’s election. The Company received aggregate proceeds of approximately $51.3 million for the issuance of the warrants, which was recorded in additional paid-in capital at issuance in the Condensed Consolidated Balance Sheets. The warrants could separately have a dilutive effect to the Company’s common stock to the extent that the market price per share of its common stock exceeds the strike price of the warrants.

Lessor Leases

Lessor Leases	9 Months Ended
Lessor Leases	Sep. 30, 2021
Leases [Abstract]
Lessor Leases	Lessor Leases Sales-Type Leases On a recurring basis, the Company enters into multi-year, sales-type lease agreements, with the majority varying in length from one The following table presents the Company’s income recognized from sales-type leases for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 (In thousands) Sales-type lease revenues $ 3,892 $ 6,033 $ 14,503 $ 19,037 Cost of sales-type lease revenues (1,699) (2,486) (5,678) (7,710) Selling profit on sales-type lease revenues $ 2,193 $ 3,547 $ 8,825 $ 11,327 Interest income on sales-type lease receivables $ 453 $ 450 $ 1,389 $ 1,437 The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at September 30, 2021 and December 31, 2020: September 30, December 31, (In thousands) Net minimum lease payments to be received $ 32,109 $ 35,331 Less: Unearned interest income portion (2,393) (2,929) Net investment in sales-type leases 29,716 32,402 Less: Current portion (1) (10,529) (10,246) Long-term investment in sales-type leases, net $ 19,187 $ 22,156 _________________________________________________ (1) The current portion of the net investment in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets. The carrying amount of the Company’s sales-type lease receivables is a reasonable estimate of fair value. The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Condensed Consolidated Balance Sheets was as follows: September 30, (In thousands) Remaining three months of 2021 $ 2,876 2022 11,012 2023 8,123 2024 5,347 2025 3,409 Thereafter 1,342 Total future minimum sales-type lease payments 32,109 Present value adjustment (2,393) Total net investment in sales-type leases $ 29,716 Operating Leases The Company entered into certain leasing agreements that were classified as operating leases prior to the adoption of ASC 842, Leases . These agreements in place prior to January 1, 2019 continue to be treated as operating leases, however any leasing agreements entered into on or after January 1, 2019 under these programs are classified and accounted for as sales-type leases in accordance with ASC 842. The operating lease arrangements generally have initial terms of one The following table represents the Company’s income recognized from operating leases for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 (In thousands) Rental income $ 2,474 $ 2,863 $ 8,278 $ 8,864
Lessor Leases	Lessor Leases Sales-Type Leases On a recurring basis, the Company enters into multi-year, sales-type lease agreements, with the majority varying in length from one The following table presents the Company’s income recognized from sales-type leases for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 (In thousands) Sales-type lease revenues $ 3,892 $ 6,033 $ 14,503 $ 19,037 Cost of sales-type lease revenues (1,699) (2,486) (5,678) (7,710) Selling profit on sales-type lease revenues $ 2,193 $ 3,547 $ 8,825 $ 11,327 Interest income on sales-type lease receivables $ 453 $ 450 $ 1,389 $ 1,437 The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at September 30, 2021 and December 31, 2020: September 30, December 31, (In thousands) Net minimum lease payments to be received $ 32,109 $ 35,331 Less: Unearned interest income portion (2,393) (2,929) Net investment in sales-type leases 29,716 32,402 Less: Current portion (1) (10,529) (10,246) Long-term investment in sales-type leases, net $ 19,187 $ 22,156 _________________________________________________ (1) The current portion of the net investment in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets. The carrying amount of the Company’s sales-type lease receivables is a reasonable estimate of fair value. The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Condensed Consolidated Balance Sheets was as follows: September 30, (In thousands) Remaining three months of 2021 $ 2,876 2022 11,012 2023 8,123 2024 5,347 2025 3,409 Thereafter 1,342 Total future minimum sales-type lease payments 32,109 Present value adjustment (2,393) Total net investment in sales-type leases $ 29,716 Operating Leases The Company entered into certain leasing agreements that were classified as operating leases prior to the adoption of ASC 842, Leases . These agreements in place prior to January 1, 2019 continue to be treated as operating leases, however any leasing agreements entered into on or after January 1, 2019 under these programs are classified and accounted for as sales-type leases in accordance with ASC 842. The operating lease arrangements generally have initial terms of one The following table represents the Company’s income recognized from operating leases for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 (In thousands) Rental income $ 2,474 $ 2,863 $ 8,278 $ 8,864

Lessee Leases

Lessee Leases	9 Months Ended
Lessee Leases	Sep. 30, 2021
Leases [Abstract]
Lessee Leases	Lessee Leases The Company has operating leases for office buildings, data centers, office equipment, and vehicles. The Company’s leases have initial terms of one The maturity schedule of future minimum lease payments under operating leases and the reconciliation to the operating lease liabilities reported on the Condensed Consolidated Balance Sheets was as follows: September 30, (In thousands) Remaining three months of 2021 $ 3,782 2022 14,783 2023 10,949 2024 9,207 2025 6,463 Thereafter 17,275 Total operating lease payments 62,459 Present value adjustment (9,014) Total operating lease liabilities (1) $ 53,445 _________________________________________________ (1) Amount consists of a current and long-term portion of operating lease liabilities of $13.0 million and $40.4 million, respectively. The current portion of the operating lease liabilities is included in accrued liabilities Operating lease costs were $3.8 million and $3.5 million for the three months ended September 30, 2021 and 2020, respectively, and $11.1 million and $10.5 million for the nine months ended September 30, 2021 and 2020, respectively. Short-term lease costs and variable lease costs were immaterial for the three and nine months ended September 30, 2021 and 2020. The following table summarizes supplemental cash flow information related to the Company’s operating leases for the nine months ended September 30, 2021 and 2020: Nine Months Ended September 30, 2021 2020 (In thousands) Cash paid for amounts included in the measurement of lease liabilities $ 11,774 $ 10,543 Right-of-use assets obtained in exchange for new lease liabilities $ 2,804 $ 1,559 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s operating leases as of September 30, 2021 and December 31, 2020: September 30, December 31, Weighted-average remaining lease term, years 5.4 5.9 Weighted-average discount rate, % 5.7 % 5.8 %

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Purchase Obligations In the ordinary course of business, the Company issues purchase orders based on its current manufacturing needs. As of September 30, 2021, the Company had non-cancelable purchase commitments of $130.7 million, of which $88.8 million are expected to be paid within the year ending December 31, 2021. Legal Proceedings The Company is currently involved in various legal proceedings. A class action lawsuit was filed against the Company, on June 5, 2019, in the Circuit Court of Cook County, Illinois, Chancery Division, captioned Corey Heard, individually and on behalf of all others similarly situated v. Omnicell, Inc., Case No. 2019-CH-06817 (the “Heard Action”). The complaint seeks class certification, monetary damages in the form of statutory damages for willful and/or reckless or, in the alternative, negligent violation of the Illinois Biometric Information Privacy Act (“BIPA”), and certain declaratory, injunctive, and other relief based on causes of action directed to allegations of violation of BIPA by the Company. The complaint was served on the Company on June 13, 2019. On July 31, 2019, the Company filed a motion to stay or consolidate the case with the action Yana Mazya, et al. v. Northwestern Lake Forest Hospital, et al., Case No. 2018-CH-07161, pending in the Circuit Court of Cook County, Illinois, Chancery Division (the “Mazya Action”). The Court subsequently, on October 10, 2019, denied the motion, without prejudice, as being moot in view of the dismissal of the claims against the Company in the Mazya Action. The Company filed a motion to dismiss the complaint in the Heard Action on October 31, 2019. The hearing on the Company’s motion to dismiss was held on September 2, 2020. The Court ruled from the bench and dismissed the complaint without prejudice giving plaintiff leave to file an amended complaint by September 30, 2020. Plaintiff filed an amended complaint on September 30, 2020 and the Company subsequently filed a motion to dismiss the amended complaint on October 28, 2020. The Company's motion to dismiss is now fully briefed, however a date for oral argument on the motion is not currently scheduled. A status conference in the case has been set for November 12, 2021. The Company intends to defend the lawsuit vigorously. On December 21, 2020, Becton, Dickinson and Company (“BD”) filed a complaint against the Company in the United States District Court for the Middle District of North Carolina, asserting claims of misappropriation under the Defend Trade Secrets Act, misappropriation under the North Carolina Trade Secrets Protection Act, unfair competition, and unfair/deceptive trade practices in violation of North Carolina law (the “BD Complaint”). This action (the “BD Action”) was commenced in relation to another action brought by BD, in the same Court (the “Related Matter”) against a former BD employee who is also a former Company employee (the “Former Employee”) alleging that the Former Employee had violated the Former Employee’s legal obligations to BD regarding BD’s confidential and trade secret information when the Former Employee allegedly downloaded certain documents from BD’s information technology system following the end of the Former Employee’s employment with BD. In connection with the Related Matter, BD, the Former Employee, and the Company entered into a protocol with the purpose of facilitating the return to BD of any BD documents that may have been resident, as a result of the Former Employee’s actions, on any devices belonging to the Former Employee or the Company. The BD Complaint seeks injunctive relief and monetary damages in the form of compensatory, punitive, and exemplary damages, attorneys’ fees and costs, and pre-judgment and post-judgment interest. On March 17, 2021, the parties filed a joint motion to stay the BD Action, which motion was granted by the Court on June 8, 2021. The stay is in place for no more than 180 days, setting the deadline for filing the Company’s answer to the BD Complaint as December 6, 2021, unless an extension to such stay is mutually agreed to by the parties and approved by the Court. The Company intends to defend the lawsuit vigorously. As required under ASC 450, Contingencies , the Company accrues for contingencies when it believes that a loss is probable and that it can reasonably estimate the amount of any such loss. The Company has not recorded any material accrual for contingent liabilities associated with the legal proceedings described above based on its belief that any potential loss, while reasonably possible, is not probable. Further, any possible range of loss in these matters cannot be reasonably estimated at this time or is not deemed material. The Company believes that it has valid defenses with respect to these legal proceedings pending against it. However, litigation is inherently unpredictable, and it is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of any of these legal proceedings or because of the diversion of management’s attention and the creation of significant expenses.

Income Taxes

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company generally provides for income taxes in interim periods based on the estimated annual effective tax rate for the year, adjusting for discrete items in the quarter in which they arise. The annual effective tax rate before discrete items was 28.2% and 30.1% for the nine months ended September 30, 2021 and 2020, respectively. The Company continued its global operational centralization activities and legal entity rationalization during the third quarter of 2021. The Company recognized an immaterial gain from such activities during the nine months ended September 30, 2021. Due to continuing global operational centralization activities in the third quarter of 2020, the Company recognized a gain on Omnicell Limited transferring its shares in Omnicell GmbH to Omnicell International, LLC, which resulted in an immaterial discrete tax expense during the nine months ended September 30, 2020. The Company recognized a discrete tax benefit related to a release of net uncertain tax benefits of $6.2 million as a result of effective settlement with tax authorities for the nine months ended September 30, 2021, and related to equity compensation in the amount of $14.5 million and $4.2 million for the nine months ended September 30, 2021 and 2020, respectively. The 2021 annual effective tax rate before discrete items differed from the statutory rate of 21% primarily due to the unfavorable impact of state income taxes, non-deductible compensation and equity charges, and non-deductible transaction costs related to merger and acquisition activities, partially offset by the favorable impact of research and development credits and a foreign derived intangible income (“FDII”) benefit deduction. The 2020 annual effective tax rate before discrete items differed from the statutory rate of 21% primarily due to the unfavorable impact of state income taxes, non-deductible compensation and equity charges, and non-deductible expenses, partially offset by the favorable impact of research and development credits and a FDII benefit deduction. On March 11, 2021, the President of the United States signed into law the “American Rescue Plan Act of 2021” (the “ARP Act”), which provides additional economic stimulus and tax credits, including the expansion and modification of the employee retention tax credit enacted by the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) and the refundable tax credits for COVID-related paid sick and family leave enacted by the Family First Act. The Company does not expect these provisions of the ARP Act to have a material impact for income taxes. The ARP Act further provides revenue raising offsets to meet budget reconciliation rules, including the expansion of the “covered employees” definition for purposes of the Internal Revenue Code of 1986, as amended, as well as Section 162(m) limitation on the deduction for excessive employee remuneration rules to be applicable for taxable years beginning after December 31, 2026. The Company will continue to evaluate the impact of these provisions of the ARP Act on income taxes. As of September 30, 2021 and December 31, 2020, the Company had gross unrecognized tax benefits of $9.8 million and $18.2 million, respectively. The $8.4 million decrease in the gross uncertain tax benefits was primarily due to a release of certain unrecognized tax benefits as a result of an effective settlement with the tax authorities in the quarter ended September 30, 2021. It is the Company’s policy to classify accrued interest and penalties as part of unrecognized tax benefits, but to record interest and penalties in interest and other income (expense), net in the Condensed Consolidated Statements of Operations. As of September 30, 2021 and December 31, 2020, the amount of accrued interest and penalties was $1.0 million and $1.4 million, respectively. The Company files income tax returns in the United States and various state and foreign jurisdictions. In the normal course of business, the Company is subject to examinations by taxing authorities, including major jurisdictions such as the United States, Germany, Italy, Netherlands, and the United Kingdom. With few exceptions, as of September 30, 2021, the Company was no longer subject to the U.S., state, and foreign examinations for years before 2017, 2016, and 2016, respectively. Although the Company believes it has adequately provided for uncertain tax positions, the provisions on these positions may change as revised estimates are made or the underlying matters are settled or otherwise resolved. It is not possible at this time to reasonably estimate changes in the unrecognized tax benefits within the next twelve months.

Employee Benefits and Share-Bas

Employee Benefits and Share-Based Compensation	9 Months Ended
Employee Benefits and Share-Based Compensation	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Employee Benefits and Share-Based Compensation	Employee Benefits and Share-Based Compensation Stock-Based Plans For a detailed explanation of the Company's stock plans, refer to Note 14, Employee Benefits and Share-Based Compensation , of the audited Consolidated Financial Statements and accompanying Notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on February 24, 2021. Share-Based Compensation Expense The following table sets forth the total share-based compensation expense recognized in the Company’s Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 (In thousands) Cost of product and service revenues $ 1,909 $ 1,758 $ 5,890 $ 5,658 Research and development 1,998 1,577 5,429 5,199 Selling, general, and administrative 9,759 7,689 27,158 22,177 Total share-based compensation expense $ 13,666 $ 11,024 $ 38,477 $ 33,034 Employee Stock Purchase Plan (“ESPP”) The following assumptions were used to value shares under the ESPP for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Expected life, years 0.5 - 2.0 0.5 - 2.0 0.5 - 2.0 0.5 - 2.0 Expected volatility, % 27.4% - 46.6% 30.4% - 53.5% 27.4% - 53.5% 30.4% - 53.5% Risk-free interest rate, % 0.1% - 1.5% 0.1% - 2.7% 0.1% - 2.6% 0.1% - 2.7% Dividend yield, % — % — % — % — % For the nine months ended September 30, 2021 and 2020, employees purchased approximately 287,000 and 333,000 shares of common stock, respectively, under the ESPP at a weighted-average price of $62.14 and $48.77, respectively. As of September 30, 2021, the unrecognized compensation cost related to the shares to be purchased under the ESPP was approximately $3.1 million and is expected to be recognized over a weighted-average period of 1.5 years. Stock Options The following assumptions were used to value stock options granted pursuant to the Company’s 2009 Equity Incentive Plan (as amended, the “2009 Plan”) for the three months ended September 30, 2020, and the nine months ended September 30, 2021 and 2020. There were no stock options granted during the three months ended September 30, 2021. Three Months Ended September 30, Nine Months Ended September 30, 2020 2021 2020 Expected life, years 4.7 4.9 4.7 Expected volatility, % 41.2 % 30.1 % 39.0 % Risk-free interest rate, % 0.3 % 0.6 % 0.7 % Estimated forfeiture rate, % 5.7 % 7.9 % 5.7 % Dividend yield, % — % — % — % The following table summarizes the stock options activity during the nine months ended September 30, 2021: Number of Weighted-Average Weighted-Average Aggregate (In thousands, except per share data) Outstanding at December 31, 2020 3,932 $ 62.50 7.8 $ 226,160 Granted 150 125.80 Exercised (648) 55.70 Expired (11) 60.64 Forfeited (180) 74.79 Outstanding at September 30, 2021 3,243 $ 66.11 7.1 $ 266,946 Exercisable at September 30, 2021 1,640 $ 51.96 5.8 $ 158,170 Vested and expected to vest at September 30, 2021 and thereafter 3,104 $ 65.35 7.0 $ 257,873 The weighted-average fair value per share of options granted during the three months ended September 30, 2020 was $23.75, and the weighted-average fair value per share of options granted during the nine months ended September 30, 2021 and 2020 was $33.89 and $25.30, respectively. The intrinsic value of options exercised during the three months ended September 30, 2021 and 2020 was $26.0 million and $4.1 million, respectively, and during the nine months ended September 30, 2021 and 2020 was $56.8 million and $16.5 million, respectively. As of September 30, 2021, total unrecognized compensation cost related to unvested stock options was $38.4 million, which is expected to be recognized over a weighted-average vesting period of 2.4 years. Restricted Stock Units (“RSUs”) The following table summarizes the restricted stock units activity under the 2009 Plan during the nine months ended September 30, 2021: Number of Weighted-Average Weighted-Average Aggregate (In thousands, except per share data) Outstanding at December 31, 2020 580 $ 72.87 1.6 $ 69,670 Granted (Awarded) 409 145.44 Vested (Released) (157) 72.39 Forfeited (54) 74.75 Outstanding and unvested at September 30, 2021 778 $ 111.00 1.7 $ 115,456 As of September 30, 2021, total unrecognized compensation cost related to RSUs was $73.4 million, which is expected to be recognized over the remaining weighted-average vesting period of 3.1 years. Restricted Stock Awards (“RSAs”) The following table summarizes the restricted stock awards activity under the 2009 Plan during the nine months ended September 30, 2021: Number of Weighted-Average (In thousands, except per share data) Outstanding at December 31, 2020 21 $ 68.11 Granted (Awarded) 11 137.36 Vested (Released) (21) 68.11 Outstanding and unvested at September 30, 2021 11 $ 137.36 As of September 30, 2021, total unrecognized compensation cost related to RSAs was $1.0 million, which is expected to be recognized over the remaining weighted-average vesting period of 0.7 years. Performance-Based Restricted Stock Units (“PSUs”) The following table summarizes the performance-based restricted stock units activity under the 2009 Plan during the nine months ended September 30, 2021: Number of Weighted-Average (In thousands, except per share data) Outstanding at December 31, 2020 155 $ 74.26 Granted 51 156.79 Vested (41) 70.68 Forfeited (7) 64.06 Outstanding and unvested at September 30, 2021 158 $ 102.29 As of September 30, 2021, total unrecognized compensation cost related to PSUs was approximately $7.0 million, which is expected to be recognized over the remaining weighted-average vesting period of 1.2 years. Summary of Shares Reserved for Future Issuance under Equity Incentive Plans The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of September 30, 2021: Number of Shares (In thousands) Share options outstanding 3,243 Non-vested restricted stock awards 947 Shares authorized for future issuance 1,514 ESPP shares available for future issuance 919 Total shares reserved for future issuance 6,623 Stock Repurchase Program On August 2, 2016, the Company’s Board of Directors (the “Board”) authorized a stock repurchase program providing for the repurchase of up to $50.0 million of the Company’s common stock (the “2016 Repurchase Program”). The 2016 Repurchase Program is in addition to the stock repurchase program approved by the Board on November 4, 2014 providing for the repurchase of up to $50.0 million of the Company’s common stock (the “2014 Repurchase Program”). As of September 30, 2021, the maximum dollar value of shares that may yet be purchased under the two repurchase programs was $54.9 million. The stock repurchase programs do not obligate the Company to repurchase any specific number of shares, and the Company may terminate or suspend the repurchase programs at any time. On September 17, 2020, the Board authorized a one-time stock repurchase transaction providing for the repurchase of up to $75.0 million of the Company’s common stock in privately negotiated transactions concurrently with the issuance of the Notes, described in Note 10, Convertible Senior Notes . In September 2020, the Company repurchased 749,300 shares of its common stock from purchasers of the Notes in the offering in privately negotiated transactions effected through one of the initial purchasers or its affiliate at an average price of $70.78 per share for an aggregate purchase price of approximately $53.0 million. There will be no further repurchases under this one-time authorization. During the three and nine months ended September 30, 2021 and 2020, the Company did not repurchase any of its outstanding common stock, including under the 2014 Repurchase Program and the 2016 Repurchase Program, other than the separately-authorized one-time stock repurchase concurrent with the offering of the Notes in September 2020.

Equity Offerings

Equity Offerings	9 Months Ended
Equity Offerings	Sep. 30, 2021
Equity [Abstract]
Equity Offerings	Equity Offerings On November 3, 2017, the Company entered into a Distribution Agreement (the “Distribution Agreement”) with J.P. Morgan Securities LLC, Wells Fargo Securities, LLC, and HSBC Securities (USA) Inc., as its sales agents, pursuant to which the Company was able to offer and sell from time to time through the sales agents up to $125.0 million maximum aggregate offering price of the Company’s common stock. Sales of the common stock pursuant to the Distribution Agreement were to be made in negotiated transactions or transactions that were deemed to be “at the market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made directly on the Nasdaq Stock Market, or sales made to or through a market maker other than on an exchange. The registration statement under which the shares that could have been sold pursuant to the Distribution Agreement expired on November 3, 2020, and, accordingly, no additional sales will be made pursuant to the Distribution Agreement. For the three and nine months ended September 30, 2020, the Company did not sell any of its common stock under the Distribution Agreement.

Restructuring Expenses

Restructuring Expenses	9 Months Ended
Restructuring Expenses	Sep. 30, 2021
Restructuring and Related Activities [Abstract]
Restructuring Expenses	Restructuring Expenses During 2020, the Company announced a company-wide organizational realignment initiative in order to more effectively align its organizational infrastructure and operations with the strategic vision of the autonomous pharmacy. During the second quarter of 2020, the Company also initiated a restructuring plan to help mitigate the adverse impact of the COVID-19 pandemic on its business and financial results. During the nine months ended September 30, 2020, the Company incurred $10.0 million of employee severance costs and related expenses. In the first quarter of 2021, the Company continued its organizational realignment initiative, incurring $2.0 million of employee severance costs and related expenses. The Company did not incur any additional restructuring expenses during the three months ended September 30, 2021. The following table summarizes the total restructuring expense recognized in the Company’s Condensed Consolidated Statements of Operations for the nine months ended September 30, 2021 and 2020: Nine Months Ended September 30, 2021 2020 (In thousands) Cost of product and service revenues $ 389 $ 2,564 Research and development 105 3,716 Selling, general, and administrative 1,526 3,681 Total restructuring expense $ 2,020 $ 9,961

Organization and Summary of S_2

Organization and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of the Company as of September 30, 2021 and December 31, 2020, the results of operations and comprehensive income for the three and nine months ended September 30, 2021 and 2020, and cash flows for the nine months ended September 30, 2021 and 2020. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) have been condensed or omitted in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying Notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on February 24, 2021, except as discussed in the section entitled “Recently Adopted Authoritative Guidance” below. The Company’s results of operations and comprehensive income for the three and nine months ended September 30, 2021, and cash flows for the nine months ended September 30, 2021 are not necessarily indicative of results that may be expected for the year ending December 31, 2021, or for any future period.
Principles of Consolidation	Principles of Consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. On September 9, 2021, the Company completed its acquisition of RxInnovation Inc., operating as FDS Amplicare (“FDS Amplicare”). The Condensed Consolidated Financial Statements include the results of operations of this recently acquired company, commencing as of the acquisition date. The significant accounting policies of the acquired business have been aligned to conform to the accounting policies of Omnicell.
Reclassifications and Adjustments	Reclassifications and AdjustmentsCertain prior-year amounts have been reclassified to conform with current-period presentation.
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s Condensed Consolidated Financial Statements and accompanying Notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. The Company’s critical accounting policies are those that affect its financial statements materially and involve difficult, subjective, or complex judgments by management. As of September 30, 2021, the Company is not aware of any events or circumstances that would require an update to its estimates, judgments, or revisions to the carrying value of its assets or liabilities.
Segment Reporting	Segment Reporting The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company's Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM
Recently Adopted and Issued Authoritative Guidance	Recently Adopted Authoritative Guidance In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes . The update simplifies the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (“ASC”) 740, Income Taxes , as well as improves consistent application of and simplifies the guidance for other areas of ASC 740 by clarifying and amending existing guidance. The Company adopted ASU 2019-12 on January 1, 2021 on a prospective basis. The adoption of this guidance did not have a material impact on the Company’s Condensed Consolidated Financial Statements. Recently Issued Authoritative Guidance In August 2020, the FASB issued ASU 2020-06 Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40) . The update simplifies the accounting for convertible debt instruments by reducing the number of accounting models and the number of embedded conversion features that could be recognized separately from the primary contract. ASU 2020-06 also enhances transparency and improves disclosures for convertible instruments and earnings per share guidance. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company will adopt ASU 2020-06 on January 1, 2022, and expects to use the modified retrospective method of transition. The Company’s adoption of the update is estimated to result in an increase in convertible senior notes, net of issuance costs, of $75.4 million; a decrease in additional paid-in capital of $72.7 million; a decrease of long-term deferred tax liabilities of $19.8 million; a decrease in long-term deferred tax assets of $0.5 million; and an increase in retained earnings of $16.7 million, all as of January 1, 2022. There was no other recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s Condensed Consolidated Financial Statements through the reporting date.
Business Combinations	The Company accounted for the acquisition of FDS Amplicare in accordance with ASC 805, Business Combinations acquisition date. The trade names intangible asset represents the fair value of brand and name recognition associated with the marketing of certain FDS Amplicare SaaS solutions. The fair value of the customer relationships intangible asset was determined based on the excess earnings method, and the fair values of the acquired technology and trade names intangible assets were determined based on the relief-from-royalty method. The key assumptions used in estimating the fair values of intangible assets included forecasted financial information; customer attrition rates; royalty rates of 10.0% and 2.0% for the acquired technology and trade names intangible assets, respectively; a discount rate of 13.0% for all intangible assets; and certain other assumptions. The customer relationships and acquired technology intangible assets are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained. The trade names intangible asset is being amortized over its estimated useful life using the straight-line method of amortization. The Company believes that the fair values assigned to the assets acquired and liabilities assumed are based on reasonable assumptions and estimates that market participants would use. Actual results may differ from these estimates and assumptions. The Company incurred approximately $4.6 million and $6.6 million in acquisition-related costs related to the FDS Amplicare acquisition during the three and nine months ended September 30, 2021, respectively. These costs were expensed as incurred, and are included in selling, general, and administrative expenses in the Company’s Condensed Consolidated Statements of Operations. The fair value of the customer relationships intangible asset was determined based on the excess earnings method; the fair values of the acquired technology and trade names intangible assets were determined based on the relief-from-royalty method; and the fair value of the non-compete agreements intangible asset was determined based on the lost profits method. The key assumptions used in estimating the fair values of intangible assets included forecasted financial information; customer attrition rates; royalty rates of 10.0% and 0.5% for the acquired technology and trade names intangible assets, respectively; a discount rate of 14.0% for all intangible assets; and certain other assumptions. The customer relationships and acquired technology intangible assets are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained. The trade names and non-compete agreements are being amortized over their estimated useful lives using the straight-line method of amortization. The Company believes that the fair values assigned to the assets acquired and liabilities assumed are based on reasonable assumptions and estimates that market participants would use. Actual results may differ from these estimates and assumptions. The Company incurred approximately $3.9 million in acquisition-related costs related to the 340B Link Business acquisition during the nine months ended September 30, 2020. These costs were expensed as incurred, and are included in selling, general, and administrative expenses in the Company’s Condensed Consolidated Statements of Operations.
Revenue Recognition	Revenue Recognition The Company earns revenues from sales of its products and related services, which are sold in the healthcare industry, its principal market. The Company’s customer arrangements typically include one or more of the following revenue categories: Connected devices, software licenses, and other. Software-enabled connected devices and software licenses that manage and regulate the storage and dispensing of pharmaceuticals, consumables blister cards, and packaging equipment and other supplies. This revenue category is often sold through long-term, sole-source agreements with multi-year co-development plans. Solutions in this category include, but are not limited to, XT Series automated dispensing systems, the XR2 Automated Central Pharmacy System, and IV compounding automation solutions. Technical services. Post-installation technical support and other related services, including phone support, on-site service, parts, and access to unspecified software updates and enhancements, if and when available. This revenue category is often supported by multi-year or annual contractual agreements. Consumables. Medication adherence packaging, labeling, and other one-time use packaging including multimed adherence packaging and single dose blister cards which are used by retail, community, and outpatient pharmacies, as well as by institutional pharmacies serving long-term care and other sites outside the acute care hospital, and are designed to improve patient engagement and adherence to prescriptions. SaaS, subscription software, and technology-enabled services. Emerging software and service solutions which are offered on a subscription basis with fees typically based either on transaction volume or a fee over a specified period of time. Solutions in this category include, but are not limited to, EnlivenHealth (formerly Population Health Solutions) inclusive of newly acquired FDS Amplicare, 340B solutions, and services associated with Omnicell One™ (formerly Performance Center), Central Pharmacy Dispensing Services, including the XR2 Automated Central Pharmacy System, and Central Pharmacy Compounding Services, including IV compounding automation solutions. The following table summarizes revenue recognition for each revenue category: Revenue Category Timing of Revenue Recognition Income Statement Classification Connected devices, software licenses, and other Point in time, as transfer of control occurs, generally upon installation and acceptance by the customer Product Technical services Over time, as services are provided, typically ratably over the service term Service Consumables Point in time, as transfer of control occurs, generally upon shipment to or receipt by customer Product SaaS, subscription software, and technology-enabled services Over time, as services are provided Service
Net Income (Loss) Per Share	Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of shares outstanding during the period. In periods of net loss, all potential common shares are anti-dilutive, so diluted net loss per share equals the basic net loss per share. In periods of net income, diluted net income per share is computed by dividing net income for the period by the basic weighted-average number of shares plus any dilutive potential common stock outstanding during the period, using the treasury stock method. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards, and restricted stock units, as well as shares the Company could be obligated to issue from its convertible senior notes and warrants, as described in Note 10, Convertible Senior Notes
Fair Value Hierarchy	The Company measures its financial instruments at fair value. The Company’s cash, cash equivalents, and restricted cash are classified within Level 1 of the fair value hierarchy as they are valued primarily using quoted market prices utilizing market observable inputs. The Company's credit facility is classified within Level 2 as the valuation inputs are based on quoted prices or market observable data of similar instruments. The Company's convertible senior notes are classified within Level 2 as the valuation inputs are based on quoted prices in an inactive market on the last day in the reporting period.
Convertible Debt	Convertible debt instruments that may be settled in cash are required to be separated into liability and equity components. The allocation to the liability component is based on the fair value of a similar instrument that does not contain an equity conversion option. Based on this debt-to-equity ratio, debt issuance costs are then allocated to the liability and equity components in a similar manner.
Commitments and Contingencies	As required under ASC 450, Contingencies , the Company accrues for contingencies when it believes that a loss is probable and that it can reasonably estimate the amount of any such loss. The Company has not recorded any material accrual for contingent liabilities associated with the legal proceedings described above based on its belief that any potential loss, while reasonably possible, is not probable. Further, any possible range of loss in these matters cannot be reasonably estimated at this time or is not deemed material. The Company believes that it has valid defenses with respect to these legal proceedings pending against it. However, litigation is inherently unpredictable, and it is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of any of these legal proceedings or because of the diversion of management’s attention and the creation of significant expenses.

Business Combinations (Tables)

Business Combinations (Tables)	9 Months Ended
Business Combinations (Tables)	Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Preliminary Allocation of the Purchase Price to the Assets Acquired and the Liabilities Assumed by the Company	The following table summarizes the preliminary purchase price for the FDS Amplicare acquisition: FDS Amplicare (In thousands) Base purchase price $ 177,000 Add: Estimated closing cash 859 Add: Estimated net working capital adjustment 1,333 Less: Assumed indebtedness (647) Total purchase price transferred $ 178,545 FDS Amplicare (In thousands) Cash and cash equivalents $ 465 Accounts receivable and unbilled receivables 4,235 Prepaid expenses 506 Other current assets 45 Total current assets 5,251 Property and equipment 444 Operating lease right-of-use assets 2,252 Goodwill 118,846 Intangible assets 69,600 Other long-term assets 51 Total assets 196,444 Accounts payable 950 Accrued compensation 1,312 Accrued liabilities 1,396 Deferred revenues 1,916 Long-term deferred tax liabilities 11,275 Long-term operating lease liabilities 920 Other long-term liabilities 130 Total liabilities 17,899 Total purchase price $ 178,545 Total purchase price, net of cash acquired $ 178,080 340B Link Business (In thousands) Accounts receivable and unbilled receivables $ 8,197 Prepaid expenses 232 Other current assets (1) 23,040 Total current assets 31,469 Property and equipment 531 Operating lease right-of-use assets 3,138 Goodwill (1) 160,268 Intangible assets 62,800 Total assets 258,206 Accounts payable 568 Accrued liabilities (1) 23,715 Long-term deferred tax liabilities (1) 6,334 Long-term operating lease liabilities 2,589 Total liabilities 33,206 Total purchase price $ 225,000 _________________________________________________ (1) During the third quarter of 2021, the Company recorded measurement period adjustments of $0.9 million to goodwill, consisting of an increase in other current assets, a decrease in accrued liabilities, and a decrease in long-term deferred tax liabilities of $0.3 million, $0.1 million, and $0.5 million, respectively.
Summary of Identifiable Intangible Assets Acquired	The identifiable intangible assets acquired and their estimated useful lives for amortization are as follows: FDS Amplicare Fair value Useful life (In thousands, except for years) Customer relationships $ 59,500 23 Acquired technology 7,700 5 - 7 Trade names 2,400 5 Total purchased intangible assets $ 69,600 340B Link Business Fair value Useful life (In thousands, except for years) Customer relationships $ 53,000 21 Acquired technology 9,000 5 Trade names 200 1 Non-compete agreements 600 3 Total purchased intangible assets $ 62,800
Pro Forma Financial Information	The following table presents certain unaudited pro forma consolidated financial information for the three and nine months ended September 30, 2021 and 2020 as if the FDS Amplicare acquisition had been completed on January 1, 2020 and the 340B Link Business acquisition had been completed on January 1, 2019. The unaudited pro forma financial information is presented for informational purposes only, and is not indicative of what would have occurred had the FDS Amplicare acquisition and the 340B Link Business acquisition taken place on January 1, 2020 and January 1, 2019, respectively. The unaudited pro forma financial information combines the historical results of the acquisitions with the Company’s consolidated historical results and includes certain adjustments including, but not limited to, amortization and depreciation of intangible assets and property and equipment acquired; imputed interest, interest expense, and amortization of debt issuance costs related to acquisitions, as applicable; and certain acquisition-related costs incurred. Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 (In thousands) Pro forma revenues $ 302,114 $ 230,099 $ 840,896 $ 689,208 Pro forma net income $ 32,050 $ 10,350 $ 65,194 $ 8,476

Revenues (Tables)

Revenues (Tables)	9 Months Ended
Revenues (Tables)	Sep. 30, 2021
Revenue Recognition [Abstract]
Summary of Revenue Recognition for Revenue Categories	The following table summarizes revenue recognition for each revenue category: Revenue Category Timing of Revenue Recognition Income Statement Classification Connected devices, software licenses, and other Point in time, as transfer of control occurs, generally upon installation and acceptance by the customer Product Technical services Over time, as services are provided, typically ratably over the service term Service Consumables Point in time, as transfer of control occurs, generally upon shipment to or receipt by customer Product SaaS, subscription software, and technology-enabled services Over time, as services are provided Service
Disaggregation of Revenues by Revenue Type	The following table summarizes the Company’s revenues disaggregated by revenue type for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 (In thousands) Connected devices, software licenses, and other $ 195,820 $ 135,037 $ 534,582 $ 403,761 Technical services 53,529 51,380 156,321 151,077 Consumables 18,150 16,300 54,424 56,591 SaaS, subscription software, and technology-enabled services 28,903 10,982 75,657 31,577 Total revenues $ 296,402 $ 213,699 $ 820,984 $ 643,006
Disaggregation of Revenues by Geographical Location	The following table summarizes the Company’s revenues disaggregated by geographic region, which is determined based on customer location, for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 (In thousands) United States $ 271,276 $ 193,639 $ 738,411 $ 579,425 Rest of world (1) 25,126 20,060 82,573 63,581 Total revenues $ 296,402 $ 213,699 $ 820,984 $ 643,006 _________________________________________________ (1) No individual country represented more than 10% of total revenues.
Contract Asset and Liabilities	The following table reflects the Company’s contract assets and contract liabilities: September 30, December 31, (In thousands) Short-term unbilled receivables, net (1) $ 17,879 $ 13,895 Long-term unbilled receivables, net (2) 14,460 17,205 Total contract assets $ 32,339 $ 31,100 Short-term deferred revenues, net $ 114,726 $ 100,053 Long-term deferred revenues 14,141 5,673 Total contract liabilities $ 128,867 $ 105,726 _________________________________________________ (1) Included in accounts receivable and unbilled receivables in the Condensed Consolidated Balance Sheets.

Net Income Per Share (Tables)

Net Income Per Share (Tables)	9 Months Ended
Net Income Per Share (Tables)	Sep. 30, 2021
Earnings Per Share [Abstract]
Basic and Diluted Net Income Per Share	The basic and diluted net income per share calculations for the three and nine months ended September 30, 2021 and 2020 were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 (In thousands, except per share data) Net income $ 29,317 $ 8,805 $ 63,868 $ 15,817 Weighted-average shares outstanding – basic 43,648 42,802 43,293 42,606 Effect of dilutive securities from stock award plans 2,087 889 2,086 1,045 Effect of convertible senior notes 2,156 — 1,816 — Effect of warrants 450 — — — Weighted-average shares outstanding – diluted 48,341 43,691 47,195 43,651 Net income per share – basic $ 0.67 $ 0.21 $ 1.48 $ 0.37 Net income per share – diluted $ 0.61 $ 0.20 $ 1.35 $ 0.36 Anti-dilutive weighted-average shares related to stock award plans 64 2,328 199 2,076 Anti-dilutive weighted-average shares related to convertible senior notes and warrants — 11,816 5,908 11,816

Balance Sheet Components (Table

Balance Sheet Components (Tables)	9 Months Ended
Balance Sheet Components (Tables)	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Components	Balance sheet details as of September 30, 2021 and December 31, 2020 are presented in the tables below: September 30, December 31, (In thousands) Inventories: Raw materials $ 40,844 $ 28,205 Work in process 7,591 7,973 Finished goods 55,824 60,120 Total inventories $ 104,259 $ 96,298 Other current assets: Funds held for customers, including restricted cash (1) $ 20,150 $ 18,164 Net investment in sales-type leases, current portion 10,529 10,246 Prepaid income taxes 5,706 10,095 Other current assets 8,032 2,539 Total other current assets $ 44,417 $ 41,044 Other long-term assets: Capitalized software, net $ 98,559 $ 94,027 Unbilled receivables, net 14,460 17,205 Deferred debt issuance costs 3,430 4,253 Other long-term assets 4,033 3,804 Total other long-term assets $ 120,482 $ 119,289 Accrued liabilities: Operating lease liabilities, current portion $ 13,009 $ 12,197 Customer fund liabilities 20,150 18,164 Advance payments from customers 8,201 6,981 Rebates and lease buyouts 39,743 21,815 Group purchasing organization fees 5,940 4,412 Taxes payable 2,049 3,520 Other accrued liabilities 15,144 13,222 Total accrued liabilities $ 104,236 $ 80,311 _________________________________________________ (1) Includes restricted cash of $0.6 million and $4.0 million as of September 30, 2021 and December 31, 2020, respectively.
Schedule of Accumulated Other Comprehensive Income (Loss)	The following table summarizes the changes in accumulated balances of other comprehensive income (loss), which consisted of foreign currency translation adjustments, for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 (In thousands) Beginning balance $ (5,491) $ (13,689) $ (5,522) $ (9,446) Other comprehensive income (loss) (2,299) 3,510 (2,268) (733) Ending balance $ (7,790) $ (10,179) $ (7,790) $ (10,179)

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
Property and Equipment (Tables)	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Balances	The following table represents the property and equipment balances as of September 30, 2021 and December 31, 2020: September 30, December 31, (In thousands) Equipment $ 87,061 $ 81,034 Furniture and fixtures 6,999 7,498 Leasehold improvements 20,365 19,517 Software 57,575 50,230 Construction in progress 8,943 7,095 Property and equipment, gross 180,943 165,374 Accumulated depreciation and amortization (115,988) (106,301) Total property and equipment, net $ 64,955 $ 59,073
Summary of Geographic Information for Property and Equipment, Net	The following table summarizes the geographic information for property and equipment, net, as of September 30, 2021 and December 31, 2020: September 30, December 31, (In thousands) United States $ 60,384 $ 53,203 Rest of world (1) 4,571 5,870 Total property and equipment, net $ 64,955 $ 59,073 _________________________________________________ (1) No individual country represented more than 10% of total property and equipment, net.

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
Goodwill and Intangible Assets (Tables)	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill	The following table represents changes in the carrying amount of goodwill: December 31, Additions (1) 340B Link Business Measurement Period Adjustments (1) Foreign currency exchange rate fluctuations September 30, (In thousands) Goodwill $ 499,309 118,846 (849) (919) $ 616,387 _________________________________________________ (1) Refer to Note 2, Business Combinations , for further information.
Carrying Amounts and Useful Lives of Intangible Assets	The carrying amounts and useful lives of intangible assets as of September 30, 2021 and December 31, 2020 were as follows: September 30, 2021 Gross carrying amount (1) Accumulated Foreign currency exchange rate fluctuations Net carrying Useful life (In thousands, except for years) Customer relationships $ 247,389 $ (73,845) $ (916) $ 172,628 10 - 30 Acquired technology 93,366 (52,631) 6 40,741 5 - 20 Trade names 9,400 (5,539) 14 3,875 1 - 12 Patents 2,890 (1,578) — 1,312 2 - 20 Non-compete agreements 600 (200) — 400 3 Total intangibles assets, net $ 353,645 $ (133,793) $ (896) $ 218,956 December 31, 2020 Gross carrying amount (1) Accumulated Foreign currency exchange rate fluctuations Net carrying Useful life (In thousands, except for years) Customer relationships $ 187,889 $ (64,254) $ (777) $ 122,858 10 - 30 Acquired technology 86,029 (44,851) 6 41,184 5 - 20 Backlog 1,150 (1,078) — 72 4 Trade names 7,850 (5,794) 14 2,070 1 - 12 Patents 2,930 (1,455) 2 1,477 2 - 20 Non-compete agreements 600 (50) — 550 3 Total intangibles assets, net $ 286,448 $ (117,482) $ (755) $ 168,211 _________________________________________________ (1) The differences in gross carrying amounts between periods are primarily due to additions of intangible assets in connection with the FDS Amplicare acquisition, partially offset by the write-off of certain fully amortized intangible assets.
Estimated Future Amortization Expense for Intangible Assets	The estimated future amortization expenses for amortizable intangible assets were as follows: September 30, (In thousands) Remaining three months of 2021 $ 7,818 2022 28,772 2023 25,580 2024 18,462 2025 16,670 Thereafter 121,654 Total $ 218,956

Debt and Credit Agreement (Tabl

Debt and Credit Agreement (Tables)	9 Months Ended
Debt and Credit Agreement (Tables)	Sep. 30, 2021
Debt Disclosure [Abstract]
Changes in Balance of Deferred Debt Issuance Costs	The following table represents changes in the balance of the Company's deferred debt issuance costs: (In thousands) Balance as of December 31, 2020 $ 4,253 Additions — Amortization (823) Balance as of September 30, 2021 $ 3,430

Convertible Senior Notes (Table

Convertible Senior Notes (Tables)	9 Months Ended
Convertible Senior Notes (Tables)	Sep. 30, 2021
Debt Disclosure [Abstract]
Convertible Debt Balances	The Notes consisted of the following balances reported in the Condensed Consolidated Balance Sheets as of September 30, 2021 and December 31, 2020: September 30, December 31, (In thousands) Liability: Principal amount $ 575,000 $ 575,000 Unamortized discount (81,870) (95,744) Unamortized debt issuance costs (10,308) (12,055) Convertible senior notes, liability component $ 482,822 $ 467,201 Convertible senior notes, equity component (1) $ 72,732 $ 72,732 _________________________________________________
Summary of Components of Interest Expense	The following table summarizes the components of interest expense resulting from the Notes recognized in interest and other income (expense), net in the Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2021: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 (In thousands) Contractual coupon interest $ 359 $ 20 $ 1,078 $ 20 Amortization of discount $ 4,679 $ 249 $ 13,874 $ 249 Amortization of debt issuance costs $ 589 $ 31 $ 1,747 $ 31

Lessor Leases (Tables)

Lessor Leases (Tables)	9 Months Ended
Lessor Leases (Tables)	Sep. 30, 2021
Leases [Abstract]
Income Recognized from Sales-Type Leases	The following table presents the Company’s income recognized from sales-type leases for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 (In thousands) Sales-type lease revenues $ 3,892 $ 6,033 $ 14,503 $ 19,037 Cost of sales-type lease revenues (1,699) (2,486) (5,678) (7,710) Selling profit on sales-type lease revenues $ 2,193 $ 3,547 $ 8,825 $ 11,327 Interest income on sales-type lease receivables $ 453 $ 450 $ 1,389 $ 1,437
Components of Sales-Type Lease Receivables	The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at September 30, 2021 and December 31, 2020: September 30, December 31, (In thousands) Net minimum lease payments to be received $ 32,109 $ 35,331 Less: Unearned interest income portion (2,393) (2,929) Net investment in sales-type leases 29,716 32,402 Less: Current portion (1) (10,529) (10,246) Long-term investment in sales-type leases, net $ 19,187 $ 22,156 _________________________________________________ (1) The current portion of the net investment in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets.
Maturity Schedule of Future Minimum Lease Payments under Sales-Type Leases	The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Condensed Consolidated Balance Sheets was as follows: September 30, (In thousands) Remaining three months of 2021 $ 2,876 2022 11,012 2023 8,123 2024 5,347 2025 3,409 Thereafter 1,342 Total future minimum sales-type lease payments 32,109 Present value adjustment (2,393) Total net investment in sales-type leases $ 29,716
Income Recognized from Operating Leases	The following table represents the Company’s income recognized from operating leases for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 (In thousands) Rental income $ 2,474 $ 2,863 $ 8,278 $ 8,864

Lessee Leases (Tables)

Lessee Leases (Tables)	9 Months Ended
Lessee Leases (Tables)	Sep. 30, 2021
Leases [Abstract]
Maturity Schedule of Future Minimum Lease Payments under Operating Leases and the Reconciliation to the Operating Lease Liabilities	The maturity schedule of future minimum lease payments under operating leases and the reconciliation to the operating lease liabilities reported on the Condensed Consolidated Balance Sheets was as follows: September 30, (In thousands) Remaining three months of 2021 $ 3,782 2022 14,783 2023 10,949 2024 9,207 2025 6,463 Thereafter 17,275 Total operating lease payments 62,459 Present value adjustment (9,014) Total operating lease liabilities (1) $ 53,445 _________________________________________________ (1) Amount consists of a current and long-term portion of operating lease liabilities of $13.0 million and $40.4 million, respectively. The current portion of the operating lease liabilities is included in accrued liabilities
Supplemental Cash Flow Information Related to Operating Leases	The following table summarizes supplemental cash flow information related to the Company’s operating leases for the nine months ended September 30, 2021 and 2020: Nine Months Ended September 30, 2021 2020 (In thousands) Cash paid for amounts included in the measurement of lease liabilities $ 11,774 $ 10,543 Right-of-use assets obtained in exchange for new lease liabilities $ 2,804 $ 1,559
Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate	The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s operating leases as of September 30, 2021 and December 31, 2020: September 30, December 31, Weighted-average remaining lease term, years 5.4 5.9 Weighted-average discount rate, % 5.7 % 5.8 %

Employee Benefits and Share-B_2

Employee Benefits and Share-Based Compensation (Tables)	9 Months Ended
Employee Benefits and Share-Based Compensation (Tables)	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Share-Based Compensation Expense	The following table sets forth the total share-based compensation expense recognized in the Company’s Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 (In thousands) Cost of product and service revenues $ 1,909 $ 1,758 $ 5,890 $ 5,658 Research and development 1,998 1,577 5,429 5,199 Selling, general, and administrative 9,759 7,689 27,158 22,177 Total share-based compensation expense $ 13,666 $ 11,024 $ 38,477 $ 33,034
Assumptions Used to Value ESPP Shares	The following assumptions were used to value shares under the ESPP for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Expected life, years 0.5 - 2.0 0.5 - 2.0 0.5 - 2.0 0.5 - 2.0 Expected volatility, % 27.4% - 46.6% 30.4% - 53.5% 27.4% - 53.5% 30.4% - 53.5% Risk-free interest rate, % 0.1% - 1.5% 0.1% - 2.7% 0.1% - 2.6% 0.1% - 2.7% Dividend yield, % — % — % — % — %
Assumptions Used to Value Stock Options Granted	The following assumptions were used to value stock options granted pursuant to the Company’s 2009 Equity Incentive Plan (as amended, the “2009 Plan”) for the three months ended September 30, 2020, and the nine months ended September 30, 2021 and 2020. There were no stock options granted during the three months ended September 30, 2021. Three Months Ended September 30, Nine Months Ended September 30, 2020 2021 2020 Expected life, years 4.7 4.9 4.7 Expected volatility, % 41.2 % 30.1 % 39.0 % Risk-free interest rate, % 0.3 % 0.6 % 0.7 % Estimated forfeiture rate, % 5.7 % 7.9 % 5.7 % Dividend yield, % — % — % — %
Summary of Share Option Activity	The following table summarizes the stock options activity during the nine months ended September 30, 2021: Number of Weighted-Average Weighted-Average Aggregate (In thousands, except per share data) Outstanding at December 31, 2020 3,932 $ 62.50 7.8 $ 226,160 Granted 150 125.80 Exercised (648) 55.70 Expired (11) 60.64 Forfeited (180) 74.79 Outstanding at September 30, 2021 3,243 $ 66.11 7.1 $ 266,946 Exercisable at September 30, 2021 1,640 $ 51.96 5.8 $ 158,170 Vested and expected to vest at September 30, 2021 and thereafter 3,104 $ 65.35 7.0 $ 257,873
Summary of Restricted Stock Unit Activity	The following table summarizes the restricted stock units activity under the 2009 Plan during the nine months ended September 30, 2021: Number of Weighted-Average Weighted-Average Aggregate (In thousands, except per share data) Outstanding at December 31, 2020 580 $ 72.87 1.6 $ 69,670 Granted (Awarded) 409 145.44 Vested (Released) (157) 72.39 Forfeited (54) 74.75 Outstanding and unvested at September 30, 2021 778 $ 111.00 1.7 $ 115,456
Summary of Restricted Stock Awards Activity	The following table summarizes the restricted stock awards activity under the 2009 Plan during the nine months ended September 30, 2021: Number of Weighted-Average (In thousands, except per share data) Outstanding at December 31, 2020 21 $ 68.11 Granted (Awarded) 11 137.36 Vested (Released) (21) 68.11 Outstanding and unvested at September 30, 2021 11 $ 137.36
Summary of Performance-Based Restricted Stock Activity	The following table summarizes the performance-based restricted stock units activity under the 2009 Plan during the nine months ended September 30, 2021: Number of Weighted-Average (In thousands, except per share data) Outstanding at December 31, 2020 155 $ 74.26 Granted 51 156.79 Vested (41) 70.68 Forfeited (7) 64.06 Outstanding and unvested at September 30, 2021 158 $ 102.29
Ordinary Shares Reserved for Future Issuance Under Equity Incentive Plans	The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of September 30, 2021: Number of Shares (In thousands) Share options outstanding 3,243 Non-vested restricted stock awards 947 Shares authorized for future issuance 1,514 ESPP shares available for future issuance 919 Total shares reserved for future issuance 6,623

Restructuring Expenses (Tables)

Restructuring Expenses (Tables)	9 Months Ended
Restructuring Expenses (Tables)	Sep. 30, 2021
Restructuring and Related Activities [Abstract]
Total Restructuring Expense Recognized in the Condensed Consolidated Statements of Operations	The following table summarizes the total restructuring expense recognized in the Company’s Condensed Consolidated Statements of Operations for the nine months ended September 30, 2021 and 2020: Nine Months Ended September 30, 2021 2020 (In thousands) Cost of product and service revenues $ 389 $ 2,564 Research and development 105 3,716 Selling, general, and administrative 1,526 3,681 Total restructuring expense $ 2,020 $ 9,961

Organization and Summary of S_3

Organization and Summary of Significant Accounting Policies (Details) $ in Thousands	1 Months Ended	9 Months Ended
	Aug. 31, 2020	Sep. 30, 2021USD ($)segment	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of operating segments \| segment		1
Number of reportable segments \| segment		1
Accounting Standards Update [Extensible Enumeration]	Accounting Standards Update 2020-06 [Member]
Convertible senior notes, net		$ 482,822		$ 467,201
Additional paid in capital		(1,002,591)		(920,359)
Long-term deferred tax liabilities		(53,313)		(39,633)
Long-term deferred tax assets		(15,866)		(15,019)
Retained earnings		$ 354,590		$ 290,722
Cumulative effect of a change in accounting principle related to credit losses \| Forecast
Accumulated Other Comprehensive Income (Loss) [Line Items]
Convertible senior notes, net			$ 75,400
Additional paid in capital			72,700
Long-term deferred tax liabilities			19,800
Long-term deferred tax assets			500
Retained earnings			$ 16,700

Business Combinations - Narrati

Business Combinations - Narrative (Details) $ in Thousands	Sep. 09, 2021USD ($)	Oct. 01, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Goodwill			$ 616,387	$ 616,387		$ 499,309
Goodwill, purchase accounting adjustments			849
FDS Amplicare
Acquired Finite-Lived Intangible Assets [Line Items]
Base purchase price	$ 177,000
Goodwill	118,846
Acquisition related costs			4,600	$ 6,600
Business combination, consideration transferred	$ 178,545
FDS Amplicare \| Discount Rate
Acquired Finite-Lived Intangible Assets [Line Items]
Measurement input used in estimating the fair values of intangible assets		0.130
FDS Amplicare \| Acquired Technology \| Royalty Rate
Acquired Finite-Lived Intangible Assets [Line Items]
Measurement input used in estimating the fair values of intangible assets		0.100
FDS Amplicare \| Trade Names \| Royalty Rate
Acquired Finite-Lived Intangible Assets [Line Items]
Measurement input used in estimating the fair values of intangible assets		0.020
340B Link Business
Acquired Finite-Lived Intangible Assets [Line Items]
Goodwill		$ 160,268
Acquisition related costs					$ 3,900
Business combination, consideration transferred		225,000
Goodwill, purchase accounting adjustments			900
Increase in other current assets, adjustment			300
Decrease in accrued liabilities, adjustment			100
Decrease in noncurrent deferred tax liability, adjustment			$ 500
Goodwill expected to be deductible for tax purposes		$ 93,700
340B Link Business \| Discount Rate
Acquired Finite-Lived Intangible Assets [Line Items]
Measurement input used in estimating the fair values of intangible assets		0.140
340B Link Business \| Acquired Technology \| Royalty Rate
Acquired Finite-Lived Intangible Assets [Line Items]
Measurement input used in estimating the fair values of intangible assets		0.100
340B Link Business \| Trade Names \| Royalty Rate
Acquired Finite-Lived Intangible Assets [Line Items]
Measurement input used in estimating the fair values of intangible assets		0.005

Business Combinations - Summary

Business Combinations - Summary of Preliminary Purchase Price (Details) - FDS Amplicare $ in Thousands	Sep. 09, 2021USD ($)
Business Acquisition [Line Items]
Base purchase price	$ 177,000
Add: Estimated closing cash	859
Add: Estimated net working capital adjustment	1,333
Less: Assumed indebtedness	(647)
Total purchase price transferred	$ 178,545

Business Combinations - Prelimi

Business Combinations - Preliminary Allocation of the Purchase Price to the Assets Acquired and the Liabilities Assumed by the Company (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Sep. 09, 2021	Dec. 31, 2020	Oct. 01, 2020
Business Acquisition [Line Items]
Goodwill	$ 616,387		$ 499,309
FDS Amplicare
Business Acquisition [Line Items]
Cash and cash equivalents		$ 465
Accounts receivable and unbilled receivables		4,235
Prepaid expenses		506
Other current assets		45
Total current assets		5,251
Property and equipment		444
Operating lease right-of-use assets		2,252
Goodwill		118,846
Intangible assets		69,600
Other long-term assets		51
Total assets		196,444
Accounts payable		950
Accrued compensation		1,312
Accrued liabilities		1,396
Deferred revenues		1,916
Long-term deferred tax liabilities		11,275
Long-term operating lease liabilities		920
Other long-term liabilities		130
Total liabilities		17,899
Total purchase price		178,545
Total purchase price, net of cash acquired		$ 178,080
340B Link Business
Business Acquisition [Line Items]
Accounts receivable and unbilled receivables				$ 8,197
Prepaid expenses				232
Other current assets				23,040
Total current assets				31,469
Property and equipment				531
Operating lease right-of-use assets				3,138
Goodwill				160,268
Intangible assets				62,800
Total assets				258,206
Accounts payable				568
Accrued liabilities				23,715
Long-term deferred tax liabilities				6,334
Long-term operating lease liabilities				2,589
Total liabilities				33,206
Total purchase price				$ 225,000

Business Combinations - Summa_2

Business Combinations - Summary of Identifiable Intangible Assets Acquired (Details) $ in Thousands	Oct. 01, 2020USD ($)
FDS Amplicare
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value	$ 69,600
FDS Amplicare \| Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value	$ 59,500
Useful life	23 years
FDS Amplicare \| Acquired technology
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value	$ 7,700
FDS Amplicare \| Acquired technology \| Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	5 years
FDS Amplicare \| Acquired technology \| Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	7 years
FDS Amplicare \| Trade names
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value	$ 2,400
Useful life	5 years
340B Link Business
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value	$ 62,800
340B Link Business \| Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value	$ 53,000
Useful life	21 years
340B Link Business \| Acquired technology
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value	$ 9,000
Useful life	5 years
340B Link Business \| Trade names
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value	$ 200
Useful life	1 year
340B Link Business \| Non-compete agreements
Acquired Finite-Lived Intangible Assets [Line Items]
Fair value	$ 600
Useful life	3 years

Business Combinations - Pro For

Business Combinations - Pro Forma Financial Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Business Combination and Asset Acquisition [Abstract]
Pro forma revenues	$ 302,114	$ 230,099	$ 840,896	$ 689,208
Pro forma net income	$ 32,050	$ 10,350	$ 65,194	$ 8,476

Revenues - Narrative (Details)

Revenues - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Revenues - Narrative (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Revenue Recognition [Abstract]
Fees to GPOs	$ 4,400	$ 2,300	$ 12,000	$ 6,900
Short-term deferred revenues, net	114,726		114,726		$ 100,053
Deferred cost of sales	24,100		24,100		21,000
Deferred revenues recognized	18,900		90,000
Short-term deferred revenues, gross					121,100
Long-term deferred revenues	$ 14,141		$ 14,141		$ 5,673
Remaining performance obligation, recognition period	10 years		10 years

Revenues - Disaggregation of Re

Revenues - Disaggregation of Revenues by Revenue Type (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue from External Customer [Line Items]
Revenues	$ 296,402	$ 213,699	$ 820,984	$ 643,006
Connected devices, software licenses, and other
Revenue from External Customer [Line Items]
Revenues	195,820	135,037	534,582	403,761
Technical services
Revenue from External Customer [Line Items]
Revenues	53,529	51,380	156,321	151,077
Consumables
Revenue from External Customer [Line Items]
Revenues	18,150	16,300	54,424	56,591
SaaS, subscription software, and technology-enabled services
Revenue from External Customer [Line Items]
Revenues	$ 28,903	$ 10,982	$ 75,657	$ 31,577

Revenues - Disaggregation of _2

Revenues - Disaggregation of Revenues by Geographic Location (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue from External Customer [Line Items]
Revenues	$ 296,402	$ 213,699	$ 820,984	$ 643,006
United States
Revenue from External Customer [Line Items]
Revenues	271,276	193,639	738,411	579,425
Rest of world
Revenue from External Customer [Line Items]
Revenues	$ 25,126	$ 20,060	$ 82,573	$ 63,581

Revenues - Contract Asset and L

Revenues - Contract Asset and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Revenue Recognition [Abstract]
Short-term unbilled receivables, net	$ 17,879	$ 13,895
Long-term unbilled receivables, net	14,460	17,205
Total contract assets	32,339	31,100
Short-term deferred revenues, net	114,726	100,053
Long-term deferred revenues	14,141	5,673
Total contract liabilities	$ 128,867	$ 105,726

Net Income Per Share (Details)

Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income	$ 29,317	$ 20,424	$ 14,127	$ 8,805	$ (4,299)	$ 11,311	$ 63,868	$ 15,817
Weighted-average shares outstanding – basic (in shares)	43,648			42,802			43,293	42,606
Weighted-average shares outstanding — diluted (in shares)	48,341			43,691			47,195	43,651
Net income per share – basic (in dollars per share)	$ 0.67			$ 0.21			$ 1.48	$ 0.37
Net income per share – diluted (in dollars per share)	$ 0.61			$ 0.20			$ 1.35	$ 0.36
Restricted Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Effect of dilutive securities (in shares)	2,087			889			2,086	1,045
Anti-dilutive weighted-average shares (in shares)	64			2,328			199	2,076
Convertible Senior Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Effect of dilutive securities (in shares)	2,156			0			1,816	0
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Effect of dilutive securities (in shares)	450			0			0	0
Convertible Senior Notes and Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive weighted-average shares (in shares)	0			11,816			5,908	11,816

Cash and Cash Equivalents and_2

Cash and Cash Equivalents and Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Sep. 25, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 481,549	$ 485,928	$ 629,171
Cash equivalents	449,100	447,200
Convertible Senior Notes \| Convertible Debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of long-term debt	917,000
Carrying value of debt	$ 482,822	$ 467,201		$ 461,800

Balance Sheet Components - Bala

Balance Sheet Components - Balance Sheet Components (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020
Inventories:
Raw materials	$ 40,844	$ 28,205
Work in process	7,591	7,973
Finished goods	55,824	60,120
Total inventories	104,259	96,298
Other current assets:
Funds held for customers, including restricted cash	20,150	18,164
Net investment in sales-type leases, current portion	10,529	10,246
Prepaid income taxes	5,706	10,095
Other current assets	8,032	2,539
Total other current assets	44,417	41,044
Other long-term assets:
Capitalized software, net	98,559	94,027
Unbilled receivables, net	14,460	17,205
Deferred debt issuance costs	3,430	4,253
Other long-term assets	4,033	3,804
Total other long-term assets	$ 120,482	$ 119,289
Accrued liabilities:
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Total accrued liabilities	Total accrued liabilities
Operating lease liabilities, current portion	$ 13,009	$ 12,197
Customer fund liabilities	20,150	18,164
Advance payments from customers	8,201	6,981
Rebates and lease buyouts	39,743	21,815
Group purchasing organization fees	5,940	4,412
Taxes payable	2,049	3,520
Other accrued liabilities	15,144	13,222
Total accrued liabilities	104,236	80,311
Cash and Cash Equivalents [Line Items]
Restricted cash	640		$ 0
Other Current Assets
Cash and Cash Equivalents [Line Items]
Restricted cash	$ 600	$ 4,000

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance at beginning of period	$ 1,052,572	$ 887,461	$ 967,503	$ 845,254
Balance at end of period	1,111,336	918,399	1,111,336	918,399
Foreign currency translation adjustments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance at beginning of period	(5,491)	(13,689)	(5,522)	(9,446)
Other comprehensive income (loss)	(2,299)	3,510	(2,268)	(733)
Balance at end of period	$ (7,790)	$ (10,179)	$ (7,790)	$ (10,179)

Property and Equipment - Proper

Property and Equipment - Property, Plant and Equipment Balances (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 180,943	$ 165,374
Accumulated depreciation and amortization	(115,988)	(106,301)
Total property and equipment, net	64,955	59,073
Equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	87,061	81,034
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	6,999	7,498
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	20,365	19,517
Software
Property, Plant and Equipment [Line Items]
Property and equipment, gross	57,575	50,230
Construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 8,943	$ 7,095

Property and Equipment - Narrat

Property and Equipment - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Depreciation	$ 5.2	$ 4.6	$ 14.9	$ 13.6

Property and Equipment - Summar

Property and Equipment - Summary of Geographic Information for Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, net	$ 64,955	$ 59,073
United States
Property, Plant and Equipment [Line Items]
Property and equipment, net	60,384	53,203
Rest of world
Property, Plant and Equipment [Line Items]
Property and equipment, net	$ 4,571	$ 5,870

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Changes in Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Goodwill [Roll Forward]
Balance at beginning of period		$ 499,309
Additions		118,846
340 Link Business Measurement Period Adjustments	$ (849)
Foreign currency exchange rate fluctuations		(919)
Balance at end of period	$ 616,387	$ 616,387

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Carrying Amounts and Useful Lives of Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Mar. 31, 2021	Sep. 30, 2021	Dec. 31, 2020
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount		$ 353,645	$ 286,448
Accumulated amortization		(133,793)	(117,482)
Foreign currency exchange rate fluctuations		(896)	(755)
Net carrying amount		218,956	168,211
Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount		247,389	187,889
Accumulated amortization		(73,845)	(64,254)
Foreign currency exchange rate fluctuations		(916)	(777)
Net carrying amount		$ 172,628	122,858
Customer relationships \| Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	10 years	10 years
Customer relationships \| Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	30 years	30 years
Acquired technology
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount		$ 93,366	86,029
Accumulated amortization		(52,631)	(44,851)
Foreign currency exchange rate fluctuations		6	6
Net carrying amount		$ 40,741	41,184
Acquired technology \| Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	5 years	5 years
Acquired technology \| Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	20 years	20 years
Backlog
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount			1,150
Accumulated amortization			(1,078)
Foreign currency exchange rate fluctuations			0
Net carrying amount			72
Useful life	4 years
Trade names
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount		$ 9,400	7,850
Accumulated amortization		(5,539)	(5,794)
Foreign currency exchange rate fluctuations		14	14
Net carrying amount		$ 3,875	2,070
Trade names \| Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	1 year	1 year
Trade names \| Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	12 years	12 years
Patents
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount		$ 2,890	2,930
Accumulated amortization		(1,578)	(1,455)
Foreign currency exchange rate fluctuations		0	2
Net carrying amount		$ 1,312	1,477
Patents \| Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	2 years	2 years
Patents \| Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life	20 years	20 years
Non-compete agreements
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount		$ 600	600
Accumulated amortization		(200)	(50)
Foreign currency exchange rate fluctuations		0	0
Net carrying amount		$ 400	$ 550
Useful life	3 years	3 years

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense of intangible assets	$ 6.3	$ 4.4	$ 18.7	$ 13.3

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Future Amortization Expense for Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Remaining three months of 2021	$ 7,818
2022	28,772
2023	25,580
2024	18,462
2025	16,670
Thereafter	121,654
Net carrying amount	$ 218,956	$ 168,211

Debt and Credit Agreement - Nar

Debt and Credit Agreement - Narrative (Details)	Sep. 22, 2020USD ($)	Nov. 15, 2019USD ($)	Nov. 30, 2019USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Debt Instrument [Line Items]
Debt issuance costs incurred and capitalized						$ 0	$ 550,000
Amortization of debt issuance costs						2,570,000	754,000
Line of Credit
Debt Instrument [Line Items]
Debt issuance costs incurred and capitalized						0
Amortization of debt issuance costs				$ 300,000	$ 200,000	800,000	$ 700,000
Line of Credit \| Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank
Debt Instrument [Line Items]
Debt issuance costs incurred and capitalized	$ 600,000		$ 2,300,000
Line of Credit \| Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank \| Minimum
Debt Instrument [Line Items]
Commitment fee rate on undrawn commitments		0.15%
Line of Credit \| Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank \| Maximum
Debt Instrument [Line Items]
Commitment fee rate on undrawn commitments		0.30%
Line of Credit \| Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank \| LIBOR
Debt Instrument [Line Items]
Spread on variable interest rate		1.00%
Line of Credit \| Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank \| LIBOR \| Minimum
Debt Instrument [Line Items]
Spread on variable interest rate		1.25%
Line of Credit \| Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank \| LIBOR \| Maximum
Debt Instrument [Line Items]
Spread on variable interest rate		2.00%
Line of Credit \| Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank \| Federal Funds
Debt Instrument [Line Items]
Spread on variable interest rate		0.50%
Line of Credit \| Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank \| LIBOR Plus 1.00% \| Minimum
Debt Instrument [Line Items]
Spread on variable interest rate		0.25%
Line of Credit \| Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank \| LIBOR Plus 1.00% \| Maximum
Debt Instrument [Line Items]
Spread on variable interest rate		1.00%
Line of Credit \| Revolving Credit Facility
Debt Instrument [Line Items]
Outstanding balance for revolving credit				$ 0		$ 0		$ 0
Line of Credit \| Revolving Credit Facility \| Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank
Debt Instrument [Line Items]
Term of debt instrument		5 years
Maximum borrowing capacity		$ 500,000,000
Line of Credit \| Revolving Credit Facility \| Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank \| Calendar Quarters Up To and Including March 31, 2021
Debt Instrument [Line Items]
Maximum secured net leverage ratio	3.50
Line of Credit \| Revolving Credit Facility \| Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank \| Calendar Quarters After March 31, 2021
Debt Instrument [Line Items]
Maximum secured net leverage ratio	3
Line of Credit \| Incremental Loan Facility \| Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank
Debt Instrument [Line Items]
Maximum borrowing capacity		250,000,000
Line of Credit \| Letter of Credit \| Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank
Debt Instrument [Line Items]
Maximum borrowing capacity		15,000,000
Line of Credit \| Swing Line Loan \| Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 25,000,000

Debt and Credit Agreement - Cha

Debt and Credit Agreement - Changes in Balance of Deferred Debt Issuance Costs (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Change In Debt Issuance Costs, Net [Roll Forward]
Balance at beginning of period	$ 4,253
Additions	0	$ 550
Balance at end of period	3,430
Line of Credit
Change In Debt Issuance Costs, Net [Roll Forward]
Balance at beginning of period	4,253
Additions	0
Amortization	(823)
Balance at end of period	$ 3,430

Convertible Senior Notes - Narr

Convertible Senior Notes - Narrative (Details)	Sep. 25, 2020USD ($)day$ / sharesshares	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Debt Instrument [Line Items]
Proceeds from issuance of convertible senior notes, net of issuance costs			$ 0	$ 559,665,000
Debt issuance costs incurred and capitalized			0	550,000
Purchase of convertible note hedge	$ 100,600,000	$ 100,625,000
Proceeds from sale of warrants	51,300,000		0	$ 51,290,000
Convertible Note Hedge
Debt Instrument [Line Items]
Deferred tax asset related to the convertible note hedge transaction	$ 25,800,000
Convertible Note Hedge Rights
Debt Instrument [Line Items]
Options and warrants to purchase shares (in shares) \| shares	5,900,000
Strike price (in dollars per share) \| $ / shares	$ 97.32
Warrants
Debt Instrument [Line Items]
Options and warrants to purchase shares (in shares) \| shares	5,900,000
Strike price (in dollars per share) \| $ / shares	$ 141.56
Convertible Senior Notes \| Convertible Debt
Debt Instrument [Line Items]
Interest rate	0.25%
Aggregate principal amount	$ 575,000,000
Additional principal amount subject to purchasers' option	75,000,000
Proceeds from issuance of convertible senior notes, net of issuance costs	559,700,000
Debt issuance costs incurred and capitalized	$ 15,300,000
Conversion ratio	0.0102751
Conversion price (in dollars per share) \| $ / shares	$ 97.32
Repurchase price as a percent of principal amount	100.00%
Aggregate principal amount of Notes that must be outstanding and not subject to redemption if the Company redeems less than all of the Notes	$ 150,000,000
Carrying value of debt	461,800,000		482,822,000		$ 467,201,000
Equity component of convertible senior notes	$ 72,700,000		$ 72,732,000		$ 72,732,000
Effective interest rate			4.18%
Remaining life of debt discount and issuance cost accretion			4 years
Maximum number of shares issuable upon conversion (in shares) \| shares	8,100,000
Excess principal amount over the if-converted value			$ 302,000,000
Convertible Senior Notes \| Convertible Debt \| Period 1
Debt Instrument [Line Items]
Threshold trading days \| day	20
Threshold consecutive trading days \| day	30
Threshold percentage of stock price trigger	130.00%
Convertible Senior Notes \| Convertible Debt \| Period 2
Debt Instrument [Line Items]
Threshold trading days \| day	5
Threshold consecutive trading days \| day	10
Threshold percentage of stock price trigger	98.00%

Convertible Senior Notes - Conv

Convertible Senior Notes - Convertible Debt Balances (Details) - Convertible Debt - Convertible Senior Notes - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Sep. 25, 2020
Liability:
Principal amount	$ 575,000	$ 575,000
Unamortized discount	(81,870)	(95,744)
Unamortized debt issuance costs	(10,308)	(12,055)
Convertible senior notes, liability component	482,822	467,201	$ 461,800
Convertible senior notes, equity component	$ 72,732	$ 72,732	$ 72,700

Convertible Senior Notes - Summ

Convertible Senior Notes - Summary of Components of Interest Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Debt Instrument [Line Items]
Amortization of discount			$ 13,874	$ 249
Amortization of debt issuance costs			2,570	754
Convertible Senior Notes \| Convertible Debt
Debt Instrument [Line Items]
Contractual coupon interest	$ 359	$ 20	1,078	20
Amortization of discount	4,679	249	13,874	249
Amortization of debt issuance costs	$ 589	$ 31	$ 1,747	$ 31

Lessor Leases - Narrative (Deta

Lessor Leases - Narrative (Details)	9 Months Ended
Lessor Leases - Narrative (Details)	Sep. 30, 2021
Lease Receivable \| Customer Concentration Risk \| U.S. Government Hospitals
Lessor, Lease, Description [Line Items]
Concentration risk percentage	69.00%
Minimum
Lessor, Lease, Description [Line Items]
Term of sales-type leases	1 year
Term of operating leases	1 year
Maximum
Lessor, Lease, Description [Line Items]
Term of sales-type leases	5 years
Term of operating leases	7 years

Lessor Leases - Income Recogniz

Lessor Leases - Income Recognized from Sales-Type Leases (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Leases [Abstract]
Sales-type lease revenues	$ 3,892	$ 6,033	$ 14,503	$ 19,037
Cost of sales-type lease revenues	(1,699)	(2,486)	(5,678)	(7,710)
Selling profit on sales-type lease revenues	2,193	3,547	8,825	11,327
Interest income on sales-type lease receivables	$ 453	$ 450	$ 1,389	$ 1,437

Lessor Leases - Components of S

Lessor Leases - Components of Sales-Type Lease Receivables (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Leases [Abstract]
Net minimum lease payments to be received	$ 32,109	$ 35,331
Less: Unearned interest income portion	(2,393)	(2,929)
Net investment in sales-type leases	29,716	32,402
Less: Current portion	(10,529)	(10,246)
Long-term investment in sales-type leases, net	$ 19,187	$ 22,156

Lessor Leases - Maturity Schedu

Lessor Leases - Maturity Schedule of Future Minimum Lease Payments under Sales-Type Leases (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Leases [Abstract]
Remaining three months of 2021	$ 2,876
2022	11,012
2023	8,123
2024	5,347
2025	3,409
Thereafter	1,342
Net minimum lease payments to be received	32,109	$ 35,331
Present value adjustment	(2,393)	$ (2,929)
Total net investment in sales-type leases	$ 29,716

Lessor Leases - Income Recogn_2

Lessor Leases - Income Recognized from Operating Leases (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Leases [Abstract]
Rental income	$ 2,474	$ 2,863	$ 8,278	$ 8,864

Lessee Leases - Narrative (Deta

Lessee Leases - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Lessee Leases - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Lessee, Lease, Description [Line Items]
Operating lease cost	$ 3.8	$ 3.5	$ 11.1	$ 10.5
Minimum
Lessee, Lease, Description [Line Items]
Term of operating leases	1 year		1 year
Maximum
Lessee, Lease, Description [Line Items]
Term of operating leases	12 years		12 years

Lessee Leases - Maturity Schedu

Lessee Leases - Maturity Schedule of Future Minimum Lease Payments under Operating Leases and the Reconciliation to the Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Leases [Abstract]
Remaining three months of 2021	$ 3,782
2022	14,783
2023	10,949
2024	9,207
2025	6,463
Thereafter	17,275
Total operating lease payments	62,459
Present value adjustment	(9,014)
Total operating lease liabilities	53,445
Current portion of operating lease liabilities	13,009	$ 12,197
Long-term portion of operating lease liabilities	$ 40,436	$ 48,897
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accrued liabilities	Accrued liabilities

Lessee Leases - Supplemental Ca

Lessee Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities	$ 11,774	$ 10,543
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 2,804	$ 1,559

Lessee Leases - Weighted-Averag

Lessee Leases - Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate (Details)	Sep. 30, 2021	Dec. 31, 2020
Leases [Abstract]
Weighted-average remaining lease term	5 years 4 months 24 days	5 years 10 months 24 days
Weighted-average discount rate	5.70%	5.80%

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	Sep. 30, 2021USD ($)
Commitments and Contingencies Disclosure [Abstract]
Non-cancelable purchase commitments	$ 130.7
Non-cancelable purchase commitments expected to be paid within the year	$ 88.8

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Income Tax Contingency [Line Items]
Annual effective tax rate			28.20%	30.10%
Unrecognized tax benefit			$ 6,200
Discrete tax benefit	$ 5,990	$ (2,156)	4,665	$ 344
Unrecognized tax benefits	9,800		9,800		$ 18,200
Unrecognized tax benefits, period decrease			8,400
Accrued interest and penalties	$ 1,000		1,000		$ 1,400
Equity Compensation
Income Tax Contingency [Line Items]
Discrete tax benefit			$ 14,500	$ 4,200

Employee Benefits and Share-B_3

Employee Benefits and Share-Based Compensation - Shared-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 13,666	$ 11,024	$ 38,477	$ 33,034
Cost of product and service revenues
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	1,909	1,758	5,890	5,658
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	1,998	1,577	5,429	5,199
Selling, general, and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 9,759	$ 7,689	$ 27,158	$ 22,177

Employee Benefits and Share-B_4

Employee Benefits and Share-Based Compensation - Assumptions Used to Value ESPP Shares (Details) - ESPP shares available for future issuance - 1997 Plan	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility (minimum)	27.40%	30.40%	27.40%	30.40%
Expected volatility (maximum)	46.60%	53.50%	53.50%	53.50%
Risk-free interest rate (minimum)	0.10%	0.10%	0.10%	0.10%
Risk-free interest rate (maximum)	1.50%	2.70%	2.60%	2.70%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	6 months	6 months	6 months	6 months
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	2 years	2 years	2 years	2 years

Employee Benefits and Share-B_5

Employee Benefits and Share-Based Compensation - Assumptions Used to Value Stock Options Granted (Details) - Stock Options	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	4 years 8 months 12 days	4 years 10 months 24 days	4 years 8 months 12 days
Expected volatility	41.20%	30.10%	39.00%
Risk-free interest rate	0.30%	0.60%	0.70%
Estimated forfeiture rate	5.70%	7.90%	5.70%
Dividend yield	0.00%	0.00%	0.00%

Employee Benefits and Share-B_6

Employee Benefits and Share-Based Compensation - Summary of Share Option Activity (Details) - 2009 Plan - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2021	Dec. 31, 2020
Number of Shares
Outstanding at beginning of period (in shares)		3,932,000
Granted (in shares)	0	150,000
Exercised (in shares)		(648,000)
Expired (in shares)		(11,000)
Forfeited (in shares)		(180,000)
Outstanding at end of period (in shares)	3,243,000	3,243,000	3,932,000
Exercisable at end of period (in shares)	1,640,000	1,640,000
Vested and expected to vest at end of period (in shares)	3,104,000	3,104,000
Weighted-Average Exercise Price
Outstanding at beginning of period (in dollars per share)		$ 62.50
Granted (in dollars per share)		125.80
Exercised (in dollars per share)		55.70
Expired (in dollars per share)		60.64
Forfeited (in dollars per share)		74.79
Outstanding at end of period (in dollars per share)	$ 66.11	66.11	$ 62.50
Exercisable at end of period (in dollars per share)	51.96	51.96
Vested and expected to vest at end of period (in dollars per share)	$ 65.35	$ 65.35
Weighted-Average Remaining Years
Outstanding		7 years 1 month 6 days	7 years 9 months 18 days
Exercisable		5 years 9 months 18 days
Vested and expected to vest		7 years
Aggregate Intrinsic Value
Outstanding	$ 266,946	$ 266,946	$ 226,160
Exercisable	158,170	158,170
Vested and expected to vest	$ 257,873	$ 257,873

Employee Benefits and Share-B_7

Employee Benefits and Share-Based Compensation - Narrative (Details) - USD ($)	Sep. 17, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Aug. 02, 2016	Nov. 04, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate purchase price for repurchased shares				$ 0	$ 53,035,000
The 2016 Repurchase Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Value of shares authorized for repurchase under stock repurchase programs (up to)						$ 50,000,000
2014 Share Repurchase Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Value of shares authorized for repurchase under stock repurchase programs (up to)							$ 50,000,000
2016 and 2014 Share Repurchase Programs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining value of shares authorized for repurchase under stock repurchase programs		$ 54,900,000		$ 54,900,000
Number of shares repurchased (in shares)		0	0	0	0
One-Time Stock Repurchase Transaction
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Value of shares authorized for repurchase under stock repurchase programs (up to)	$ 75,000,000
Number of shares repurchased (in shares)	749,300
Average price of repurchased shares (in dollars per share)	$ 70.78
Aggregate purchase price for repurchased shares	$ 53,000,000
1997 Plan \| ESPP shares available for future issuance
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares purchased under ESPP (in shares)				287,000	333,000
Weighted-average price of shares purchased (in dollars per share)				$ 62.14	$ 48.77
Unrecognized compensation cost		$ 3,100,000		$ 3,100,000
Weighted average period of compensation cost not yet recognized				1 year 6 months
2009 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted (in shares)		0		150,000
Weighted-average fair value of options granted (in dollars per share)			$ 23.75	$ 33.89	$ 25.30
Intrinsic value of options exercised		$ 26,000,000	$ 4,100,000	$ 56,800,000	$ 16,500,000
Unrecognized compensation cost of unvested stock options		38,400,000		$ 38,400,000
2009 Plan \| Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average period of compensation cost not yet recognized				2 years 4 months 24 days
2009 Plan \| RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average period of compensation cost not yet recognized				3 years 1 month 6 days
Unrecognized compensation cost		73,400,000		$ 73,400,000
2009 Plan \| RSAs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average period of compensation cost not yet recognized				8 months 12 days
Unrecognized compensation cost		1,000,000		$ 1,000,000
2009 Plan \| PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average period of compensation cost not yet recognized				1 year 2 months 12 days
Unrecognized compensation cost		$ 7,000,000		$ 7,000,000

Employee Benefits and Share-B_8

Employee Benefits and Share-Based Compensation - Summary of Restricted Stock Unit Activity (Details) - RSUs - 2009 Plan - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Number of Shares
Outstanding at beginning of period (in shares)	580
Granted (Awarded) (in shares)	409
Vested (Released) (in shares)	(157)
Forfeited (in shares)	(54)
Outstanding and unvested at end of period (in shares)	778	580
Weighted-Average Grant Date Fair Value
Outstanding at beginning of period (in dollars per share)	$ 72.87
Granted (Awarded) (in dollars per share)	145.44
Vested (Released) (in dollars per share)	72.39
Forfeited (in dollars per share)	74.75
Outstanding and unvested at end of period (in dollars per share)	$ 111	$ 72.87
Weighted-Average Remaining Years
Outstanding and unvested	1 year 8 months 12 days	1 year 7 months 6 days
Aggregate Intrinsic Value
Outstanding and unvested	$ 115,456	$ 69,670

Employee Benefits and Share-B_9

Employee Benefits and Share-Based Compensation - Summary of Restricted Stock Award Activity (Details) - RSAs - 2009 Plan shares in Thousands	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Number of Shares
Outstanding at beginning of period (in shares) \| shares	21
Granted (Awarded) (in shares) \| shares	11
Vested (Released) (in shares) \| shares	(21)
Outstanding and unvested at end of period (in shares) \| shares	11
Weighted-Average Grant Date Fair Value
Outstanding at beginning of period (in dollars per share) \| $ / shares	$ 68.11
Granted (Awarded) (in dollars per share) \| $ / shares	137.36
Vested (Released) (in dollars per share) \| $ / shares	68.11
Outstanding and unvested at end of period (in dollars per share) \| $ / shares	$ 137.36

Employee Benefits and Share-_10

Employee Benefits and Share-Based Compensation - Summary of Performance-Based Restricted Stock Activity (Details) - Performance-Based Restricted Stock - 2009 Plan shares in Thousands	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Number of Shares
Outstanding at beginning of period (in shares) \| shares	155
Granted (Awarded) (in shares) \| shares	51
Vested (Released) (in shares) \| shares	(41)
Forfeited (in shares) \| shares	(7)
Outstanding and unvested at end of period (in shares) \| shares	158
Weighted-Average Grant Date Fair Value
Outstanding at beginning of period (in dollars per share) \| $ / shares	$ 74.26
Granted (Awarded) (in dollars per share) \| $ / shares	156.79
Vested (Released) (in dollars per share) \| $ / shares	70.68
Forfeited (in dollars per share) \| $ / shares	64.06
Outstanding and unvested at end of period (in dollars per share) \| $ / shares	$ 102.29

Employee Benefits and Share-_11

Employee Benefits and Share-Based Compensation - Summary of Shares Reserved for Future Issuance Under Equity Incentive Plans (Details) shares in Thousands	Sep. 30, 2021shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	6,623
Share options outstanding
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	3,243
Non-vested restricted stock awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	947
Shares authorized for future issuance
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	1,514
ESPP shares available for future issuance
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	919

Equity Offerings (Details)

Equity Offerings (Details)	Nov. 03, 2017USD ($)
Distribution Agreement
Subsidiary, Sale of Stock [Line Items]
Maximum aggregate offering price	$ 125,000,000

Restructuring Expenses - Narrat

Restructuring Expenses - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
Restructuring Expenses - Narrative (Details) - USD ($)	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2021	Sep. 30, 2020
Restructuring and Related Activities [Abstract]
Restructuring expenses	$ 0	$ 2,000,000	$ 2,020,000	$ 9,961,000

Restructuring Expenses - Total

Restructuring Expenses - Total Restructuring Expense Recognized in the Condensed Consolidated Statements of Operations (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2021	Sep. 30, 2020
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	$ 0	$ 2,000,000	$ 2,020,000	$ 9,961,000
Cost of product and service revenues
Restructuring Cost and Reserve [Line Items]
Restructuring expenses			389,000	2,564,000
Research and development
Restructuring Cost and Reserve [Line Items]
Restructuring expenses			105,000	3,716,000
Selling, general, and administrative
Restructuring Cost and Reserve [Line Items]
Restructuring expenses			$ 1,526,000	$ 3,681,000